AROMATHERAPY COMPOSITIONS

BACKGROUND OF THE INVENTION

Field of the Invention

[0001] The present invention relates to aromatherapy compositions that possess therapeutic effects. More particularly, the present invention relates to essential oil compositions, and even more particularly to anxiolytic, nootropic, soporific and analeptic essential oil compositions comprising specific mixtures of essential oils formulated for aerosolization, orthonasal, retronasal, topical or transdermal delivery for the purpose of providing a therapeutic effect.

Background Art

[0002] People around the world suffer from either an illness or a disorder, which may be characterized by symptoms that include problems with memory, visual perception, problem solving, self-management, the inability to focus, high anxiety, insomnia, low libido, chronic pain, acute pain, inflammation, fatigue, respiratory failure, indigestion, addiction, depression or compromised immunity. These symptoms can occur and be treated within a short period, such as in a day or week, but can also persist over prolonged periods, such as years or an entire lifetime.

[0003] A number of treatments exist for treating these symptoms, including lifestyle modifications, pharmaceuticals, and all-natural or holistic treatments. However, effective lifestyle modifications are difficult to maintain and may not be feasible for many people, while effective pharmaceutical treatments are typically expensive, require a prescription, and involve some risk of undesirable side effects. By contrast, the efficacy of the overwhelming majority of holistic treatments remains questionable, as scientific validation studies have been plagued by irreproducibility.

[0004] Essential oils have been used for millennia to effect changes in human physiology. Essential oils are distilled plant extracts composed of a mixture of terpenes and other aromatic compounds that are either ingested or inhaled for the purpose of altering mood, cognition, and psychological or physical well-being. When introduced to the body, traditionally by diffuse nasal inhalation, essential oils can have immediate and long-lasting beneficial effects. However, traditional diffusion-based aromatherapy delivery systems have manifold problems. Candles and incense require the high heat of combustion which destroys the active components of many essential oils. Steam or passive diffusers often have insufficient dose delivery due to the physical properties of the aromatic compounds. Additionally, essential oil room diffusers may be prohibited by applicable building codes or business policies, and can be offensive to others. The physical properties of essential oils also make them difficult to formulate into appropriate aerosol formulations for efficient absorption into the nasal mucosa. Ingestion of essential oils can be efficacious depending on the specific molecular composition, but is often ineffective due to significant loss of active compounds during first pass metabolism in the liver.

[0005] Therefore, there is a need for advancements in essential oil compositions and delivery for improving the overall health of an individual.

SUMMARY OF THE INVENTION

[0006] The present invention provides specific combinations of essential oils and/or their constituent molecules to produce therapeutic compositions that may be absorbed through the nasal sinuses, skin, respiratory pathway and/or used to bathe the olfactory bulb to alleviate symptoms and produce a surprising range of therapeutic effects. The effects may include increased energy levels, enhanced cognitive function, reduced inflammation, pain relief, improved digestive health, improved sleep, reduced anxiety, improved mood, increased libido, improved immune function and enhanced respiratory performance. Some of the individual essential oils have therapeutic effects that are synergistically enhanced when specific combinations and ratios are used as disclosed herein. In addition, the compositions disclosed herein are designed to be safe and effective when delivered to a subject via a portable battery powered aromatherapy diffuser or vaporizer.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0007] While the terms used herein are believed to be well understood by one of ordinary skill in the art, definitions are set forth herein to facilitate explanation of the subject matter disclosed herein.

[0008] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the subject matter disclosed herein belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the presently disclosed subject matter, representative methods, devices, and materials are described herein.

[0009] As used herein, the term “subject” refers to any animal (e.g., a mammal), including, but not limited to, humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment. Preferably the subject is a human.

[00010] As used herein, treating/treatment means any manner in which one or more of the symptoms of a disease or disorder are ameliorated or otherwise beneficially altered. [00011] As used herein, therapeutic effect refers to the response(s) after a treatment of any kind, the results of which are judged to be useful or favorable. This is true whether the result was expected, unexpected, or even an unintended consequence.

[00012] The terms “a”, “an”, and “the” refer to “one or more” when used in this application, including the claims. Thus, for example, reference to “a terpene” includes a plurality of molecules of the terpene, and so forth. The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

[00013] All references to singular characteristics or limitations of the present disclosure shall include the corresponding plural characteristic(s) or limitation(s) and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made.

[00014] All combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.

[00015] The methods and devices of the present disclosure, including components thereof, can comprise, consist of, or consist essentially of the essential elements and limitations of the embodiments described herein, as well as any additional or optional components or limitations described herein or otherwise useful.

[00016] Unless otherwise indicated, all numbers expressing physical dimensions, quantities of ingredients, properties such as reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about”. Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and claims are approximations that can vary depending upon the desired properties sought to be obtained by the presently disclosed subject matter. [00017] As used herein, the term “about,” when referring to a value or to an amount of mass, weight, time, volume, concentration, percentage or a physical dimension such as length, width, or diameter, is meant to encompass variations of in some embodiments ±20%, in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified value or amount, as such variations are appropriate to perform the disclosed methods.

[00018] Values presented herein as percentages are to be understood as referring to an amount by volume. For example, a composition containing 75% component A and 25% component B should be understood to mean that such composition includes 75% by volume of component A and 25% by volume of component B.

[00019] As used herein, ranges can be expressed as from “about” one particular value, and/or to “about” another particular value. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed. [00020] The term “composition” as used herein refers not only to aromatherapeutic compositions for treatment purposes, in particular not only pharmaceuticals and medications or medical products, but also foods, nutritional supplements, food ingredients or additives, flavor compositions, topical creams, and homeopathic agents.

[00021] The terms “breath” and “breathing” as used herein refer to bathing the olfactory bulb at the bridge of the nose in a substance, such as a terpene. The terms “breath” and “breathing” specifically do not require inhalation of a substance into the lungs. Rather, “breath” and “breathing” specifically include introducing a substance into the body via the oral cavity, and expelling the substance through the nose such that the substance is exposed directly to the olfactory bulb and compounds may be delivered to the user via absorption through the nasal mucosa. “Breath” and “breathing” also specifically include the process of retronasal olfaction.

Compositions and Kits

[00022] Compositions, each with a specific synergistic effect, which can be absorbed through the nasal sinuses, skin, respiratory system and/or used to bathe the olfactory bulb after oral inhalation and nasal exhalation, are disclosed herein. Each oil consists of three to five major terpene constituents that have an additive or synergistic effect when combined with the terpenes of other specific essential oils. The specific combinations thereof are the subject of the present invention.

[00023] While each of the foregoing essential oils can produce a specific set of therapeutic effects based upon the action of their terpenes, these effects are synergistically enhanced when specific combinations and ratios are used in a composition formulated for nasal, topical, transdermal or respiratory delivery, particularly when such composition includes free terpenes as an additional ingredient. Accordingly, a therapeutic essential oil composition can be prepared by mixing a blend of at least one primary essential oil, at least one secondary essential oil, formulated for nasal, topical, transdermal or respiratory delivery with or without vegetable glycerin, water, and an emulsifier into a liquid solution. The primary and secondary essential oils preferably used within the invention are shown in Table 1

TABLE 1

PRIMARY & SECONDARY ESSENTIAL OILS

Spearmint Caraway

Cinnamon leaf Sughanda Kokila

Nutmeg Clary Sage

Rosemary Sage

Cardamom Black Pepper

Frankincense Holy Basil

Ginger Grapefruit

Bergamot Litsea Cubeba

Melissa Coffee C02

Eucalyptus,

Allspice

Lemon

Anise Copaiba

Lemon Mandarin Yellow

Orange Bitter Orange Sweet

Parsley Seed Mandarin Green

Fennel Lavender

Maqoram Vanilla CO2

Petitgrain Thyme ct. linalool Peppermint Dill seed

Orange wild Hyssop

Oregano Geranium

Rosemary ct.

Basil cineole

Chamomile Kava Kava

Lemon Grass Neroli

Sandalwood Turmeric

Benzoin Cacao

Cinnamon Bark Clove Bud

Coconut Ketone Coconut Pulp

Cognac Davana

Hops Liquidambar

Massoia Bark Orange Blood

Peru Balsam Rose Otto

Sandalwood

Siam Wood Royal Hawaiin

Commint Palo Santo

Frankincense

Galangal

Frereana

Fir, Douglas Juniper Berry

Eucalyptus

Cedarwood

Dives

Eucalyptus, Narrow

Opopanax Leaf

Tea Tree Cardamom

Cassia Ginger grass

Rosalina Ravensara

Coffee Bean

Fenugreek CO2 CO2

Spikenard Red Ginger CO2

Spike Lavender Owyhee

Ravintsara Frankincense Carterii

Frankincense

Helichrysum

CO2

Spikenard

Jasmine

Jatamansi

Nerolina Pine

Cypress Leaf Juniper Leaf

Eucalyptus, Blue

Lime Gum

Manuka Neroli

Tangerine Ylang Ylang

Elemi Fir, Balsam

Spruce Nagarmotha

Galbanum CO2 Patchouli

Commint Palo Santo

Eucalyptus

Benzoin

Dives

[00024] The primary and secondary essential oils preferably used within the invention may be derived or extracted from the genus Pimenta, Pimpinella, Copaifera, Boswellia, Citrus, Petroselinum, Piper, Rosmarinus, Salvia, Mentha, Cananga, Anethum, Melaleuca, Eucalyptus, Leptospermum, Vanilla, Pimenta, Carum, Cinnamomum, Jasminum, Lavandula, Pogostemon, Cupressus, Pinus, Canarium, Juniperus, Pseudotsuga, Santalum, Pelargonium, Abies, Zingiber, Picea, Litsea, Cyperus, Curcuma, Ferula, Cedrus, Cymbopogon, Thymus, Artemisia, Melaleuca, Helichrysum, Nardostachys, Matricaria, Anthemis, Eugenia, Elettaria, Myristica, Cryptocarya, Illicium, Coffea, Myroxylon, Trigonella, Commiphora, Origanum, Ocimum, Hyssopus and Foeniculum.

[00025] In one embodiment of the invention, the blend of the primary essential and secondary essential oil is in an amount from about 5% to about 95% by volume, from about 10% to about 90% by volume, from about 15% to about 95% by volume, from about 20% to about 90% by volume, from about 25% to about 85% by volume, from about 30% to about 80% by volume, from about 35% to about 75% by volume, from about 40% to about 70% by volume, from about 45% to about 65% by volume, from about 50% to about 60% by volume, from about 5% to about 10% by volume, from about 5% to about 20% by volume, from about 5% to about 25% by volume, from about 5% to about 30% by volume, from about 5% to about 35% by volume, from about 5% to about 40% by volume, from about 5% to about 45% by volume, from about 5% to about 50% by volume, from about 5% to about 55% by volume, from about 5% to about 60% by volume, from about 5% to about 65% by volume, from about 5% to about 70% by volume, from about 5% to about 75% by volume, from about 5% to about 80% by volume, from about 5% to about 90% by volume, from about 90% to about 95% by volume, from about 85% to about 95% by volume, from about 80% to about 95% by volume, from about 75% to about 95% by volume, from about 70% to about 95% by volume, from about 65% to about 95% by volume, from about 60% to about 95% by volume, from about 55% to about 95% by volume, from about 50% to about 95% by volume, from about 45% to about 95% by volume, from about 40% to about 95% by volume, from about 35% to about 95% by volume, from about 30% to about 95% by volume, from about 25% to about 95% by volume, from about 20% to about 95% by volume, from about 15% to about 95% by volume, from about 10% to about 95% by volume of the aromatherapy composition. [00026] In another embodiment of the invention, the blend of the primary essential and secondary essential oil is in an amount of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% in the aromatherapy composition.

[00027] In another embodiment of the invention, the vegetable glycerin is an amount of from about 5% to about 95% by volume, from about 10% to about 90% by volume, from about 15% to about 95% by volume, from about 20% to about 90% by volume, from about 25% to about 85% by volume, from about 30% to about 80% by volume, from about 35% to about 75% by volume, from about 40% to about 70% by volume, from about 45% to about 65% by volume, from about 50% to about 60% by volume, from about 5% to about 10% by volume, from about 5% to about 20% by volume, from about 5% to about 25% by volume, from about 5% to about 30% by volume, from about 5% to about 35% by volume, from about 5% to about 40% by volume, from about 5% to about 45% by volume, from about 5% to about 50% by volume, from about 5% to about 55% by volume, from about 5% to about 60% by volume, from about 5% to about 65% by volume, from about 5% to about 70% by volume, from about 5% to about 75% by volume, from about 5% to about 80% by volume, from about 5% to about 90% by volume, from about 90% to about 95% by volume, from about 85% to about 95% by volume, from about 80% to about 95% by volume, from about 75% to about 95% by volume, from about 70% to about 95% by volume, from about 65% to about 95% by volume, from about 60% to about 95% by volume, from about 55% to about 95% by volume, from about 50% to about 95% by volume, from about 45% to about 95% by volume, from about 40% to about 95% by volume, from about 35% to about 95% by volume, from about 30% to about 95% by volume, from about 25% to about 95% by volume, from about 20% to about 95% by volume, from about 15% to about 95% by volume, from about 10% to about 95% by volume of the aromatherapy composition.

[00028] In another embodiment of the invention, the vegetable glycerin is in an amount of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% in the aromatherapy composition. [00029] Another aspect of the present invention is directed to a composition for use in aromatherapy. The composition includes a blend of at least one primary essential oil and at least one secondary essential oil, wherein the blend is in an amount of from about 15% to about 25% by volume. In addition, the composition includes vegetable glycerin in an amount of about 75% to about 85% by volume.

[00030] In one embodiment, the at least one primary essential oil and at least one secondary essential oil are selected from the group consisting of spearmint, cinnamon leaf, nutmeg, rosemary, cardamom, frankincense, ginger, bergamot, melissa, eucalyptus lemon, caraway, sughanda kokila, clary sage, sage, black pepper, holy basil, grapefruit, litsea cubeba, and coffee CO2.

[00031] In another embodiment, the composition comprises Pimenta officinalis, Pimpinella anisum, Copaifera officinalis, Boswellia sacra Flueck, Citrus limon, Citrus reticulata Blanco, Citrus aurantium var. amara, Citrus sinensis (l.) osbeck, Petroselinum sativum, Piper nigrum, Rosmarinus officinalis (L.) ct cineole, Salvia officinalis L. and Mentha spicata L..

[00032] In one embodiment, the composition comprises 0.1% to 1.0 % Pimenta officinalis, 0.1% to 1.0 % Pimpinella anisum, 2.0% to 3.0% Copaifera officinalis, 1.0% to 2.0% Boswellia sacra Flueck., 0.5% to 1.5% Citrus limon, 0.5% to 1.5% Citrus reticulata Blanco, 3.5% to 4.5% Citrus aurantium var. amara, 1.5% to 2.5% Citrus sinensis (l.) osbeck, 0.5% to 1.5% Petroselinum sativum, 1.5% to 2.5% Piper nigrum, 0.5% to 1.5% Rosmarinus officinalis (L.) ct cineole, 0.1% to 1.0% Salvia officinalis L., and 1.5% to 2.5% _> Mentha spicata L.. [00033] In another embodiment, the composition comprises 2-Methyl-3-buten-2-ol; Isoamyl alcohol; 2-Methylbutanol; Toluene; Hexanal; (Z)-Salvene; (3Z)-Hexenol; Hexanol; trans-2,5-Diethyltetrahydrofuran; Hashishene; Tricyclene; a-Thujene; a-Pinene; a-Fenchene; Camphene; Thuja-2,4(10)-diene; Sabinene; b-Pinene; 6-Methyl-5-hepten-2-one; Myrcene; 6- Methyl-5-hepten-2-ol; Octan-3-ol; a-Phellandrene; Pseudolimonene; Octanal; A3-Carene: a- Terpinene; para-Cymene; Limonene; b-Phellandrene; 1,8-Cineole; Lavender lactone; Benzyl alcohol; (Z)^-Ocimene; (E)^-Ocimene; g-Terpinene; cis-Sabinene hydrate; cis-Linalool oxide (fur.); Octanol; Isoterpinolene; para-Cymenene; Terpinolene; trans-Linalool oxide (fur.); a-Pinene oxide; Rosefuran; Linalool; a-Thujone; Nonanal; b-Thujone; trans-para- Mentha-2,8-dien-l-ol; a-Campholenal; cis-Limonene oxide; trans-Limonene oxide; cis-para- Mentha-2,8-dien-l-ol; Camphor; Benzeneacetonitrile; trans-Pinocarveol; (E)-Myroxide; meta-Mentha-4,6-dien-8-ol; Citronellal; Menthone; Pinocarvone; Bomeol; Menthol; Terpinen-4-ol; para-Cymen-8-ol; a-Terpineol; cis-Dihydrocarvone; Methylchavicol; trans- Isopiperitenol; trans-Dihydrocarvone; Verbenone; Decanal; Octyl acetate; trans-Carveol; Methyl decyl ether; Citronellol; cis-Carveol; Carvone; Neral; Geraniol; Linalyl acetate; Isopiperitenone; Geranial; Perillaldehyde; trans-Carvone oxide; Bomyl acetate; Dihydroedulan; (E)-Anethole; Dihydroedulan; Carvacrol; Dihydrocarvyl acetate; Bicycloelemene; d-Elemene; a-Cubebene; Eugenol; a-Ylangene; a-Copaene; b-Bourbonene; Geranyl acetate; b-Elemene; (Z)-Jasmone; Dimethyl anthranilate; Methyleugenol; b- Caryophyllene; /.v-a-Bergamotene: b-Ylangene; /ra/ v-a-Bergamotene: a-Guaiene; Isogermacrene D; a-Humulene; allo-Aromadendrene; /ra/ v-Cadina- 1 (6).4-diene: g- Muurolene; Germacrene D; b-Selinene; Bicyclogermacrene; a-Selinene; a-Muurolene; e- Amorphene; b-Bisabolene; g-Cadinene; (3A ^’ .6A ^’ )-a-Farnesene: d-Cadinene; Myristicin; trans- Calamenene; /ra/ v-Cadina- 1.4-diene: a-Calacorene; Isocaryophyllene epoxide B; Elemicin; Caryophyllenyl alcohol; Spathulenol; Caryophyllene oxide; Caryophyllene oxide isomer; Viridiflorol; Carotol; l,2,3,4-Tetramethoxy-5-allylbenzene; Humulene epoxide II; Junenol; Guaia-6,10(14)-dien-4b-ol; Isospathulenol; x-Cadinol; x-Muurolol; a-Muurolol; a-Cadinol; (3Z)-Caryophylla-3,8(13)-dien-5b-ol; Apiole; Juniper camphor; a-Sinensal; ( E )- Pseudoisoeugenyl 2-Methylbutyrate; Epoxypseudoisoeugenyl 2-Methylbutyrate; meta- Camphorene; (3£)-Cembrene A; Citropten; para-Camphorene; Manool; Kolavelool; Osthole; Cembrenol; Bergapten; Serratol; Isoauraptene; Meranzin; Copalol; Kolavenol; and/or Pentamethoxyflavone isomer.

[00034] In one embodiment, the composition comprises at most 0.005% 2-Methyl-3- buten-2-ol; at most 0.005% Isoamyl alcohol; at most 0.005% 2-Methylbutanol; at most 0.005% Toluene; at most 0.005% Hexanal; at most 0.005% (Z)-Salvene; at most 0.005% (3Z)-Hexenol; at most 0.005% Hexanol; between 0.005% to 0.05% trans-2,5- Diethyltetrahydrofuran; between 0.005% to 0.05% Hashishene; between 0.05% to 0.10% Tricyclene; 0.5% to 1.5% a-Thujene; 5.0% to 7.0% a-Pinene; 0.5% to 1.5% a-Fenchene; 0.5% to 1.5% Camphene; 0.001% to 0.005% Thuja-2, 4(10)-diene; 3.0% to 4.0% Sabinene; 3.0% to 4.0% b-Pinene; 0.01% to 0.05% 6-Methyl-5-hepten-2-one; 1.0% to 2.0% Myrcene; at most 0.005% 6-Methyl-5-hepten-2-ol; 0.01% to 0.05% Octan-3-ol; 0.1% to 0.5% a- Phellandrene; 0.1 to 0.5% Pseudolimonene; 0.01% to 0.05% Octanal; 0.5% to 1.5% D3- Carene; 0.05% to 0.15% a-Terpinene; 0.4% to 0.6% para-Cymene; 40% to 45% Limonene; 40% to 45% b-Phellandrene; 40% to 45% 1,8-Cineole; 0.1% to 0.2% Lavender lactone; 0.1% to 0.2% Benzyl alcohol; 0.1% to 0.2% (Z)^-Ocimene; 0.05% to 0.1% (E)^-Ocimene; 1.0% to 2.0% g-Terpinene; 0.01% to 0.1% cis-Sabinene hydrate; at most 0.005% cis-Linalool oxide (fur.); 0.005% to 0.015% Octanol; 0.005% to 0.015% Isoterpinolene; 0.1 % to 0.2% para- Cymenene; 0.1% to 0.2% Terpinolene; 0.1% to 0.2% trans-Linalool oxide (fur.); 0.005% to 0.015% a-Pinene oxide; at most 0.005% Rosefuran; 1.0% to 2.0% Linalool; 1.0% to 2.0% a- Thujone; 0.01% to 0.05% Nonanal; 0.01% to 0.05% b-Thujone; 0.01% to 0.05% trans-para- Mentha-2,8-dien-l-ol; 0.005% to 0.015% a-Campholenal; 0.01% to 0.05% cis-Limonene oxide; 0.01% to 0.05% trans-Limonene oxide; 0.01% to 0.05% cis-para-Mentha-2,8-dien-l- ol; 1.0% to 2.0% Camphor; 1.0% to 2.0% Benzeneacetonitrile; 1.0% to 2.0% trans- Pinocarveol; 0.01% to 0.05% (E)-Myroxide; 0.005% to 0.015% meta-Mentha-4,6-dien-8-ol; 0.01% to 0.05% Citronellal; 0.01% to 0.05% Menthone; 0.005% to 0.015% Pinocarvone; 0.1% to 0.5% Bomeol; 0.05% to 0.15% Menthol; 0.15% to 0.25% Terpinen-4-ol; 0.005% to 0.015% para-Cymen-8-ol; 0.1% to 0.2% a-Terpineol; 0.1% to 0.2% cis-Dihydrocarvone; 0.01% to 0.05% Methylchavicol; 0.01% to 0.05% trans-Isopiperitenol; 0.01% to 0.05% trans- Dihydrocarvone; 0.03% to 0.1% Verbenone; 0.01% to 0.1% Decanal; 0.01% to 0.1% Octyl acetate; 0.01% to 0.1% trans-Carveol; 0.01% to 0.1% Methyl decyl ether; 0.01% to 0.1% Citronellol; 0.01% to 0.1% cis-Carveol; 5.0% to 7.0% Carvone; 5.0% to 7.0% Neral; 0.01% to 0.1% Geraniol; 0.01% to 0.1% Linalyl acetate; 0.01% to 0.1% Isopiperitenone; 0.1% to 0.2% Geranial; 0.1% to 0.2% Perillaldehyde; 0.005% to 0.01% trans-Carvone oxide; 3.0% to 4.0% Bomyl acetate; 3.0% to 4.0% Dihydroedulan; 3.0% to 4.0% (E)-Anethole; 0.005% to 0.015% Dihydroedulan; 0.005% to 0.015% Carvacrol; 0.01% to 0.05% Dihydrocarvyl acetate; 0.005% to 0.015% Bicycloelemene; 0.2% to 0.4% d-Elemene; 0.05% to 0.15% a- Cubebene; 2.0% to 3.0% Eugenol; 0.05% to 0.15% a-Ylangene; 0.5% to 0.7% a-Copaene; 0.1% to 0.5% b-Bourbonene; 0.05% to 0.15% Geranyl acetate; 0.1% to 0.5% b-Elemene; 0.01% to 0.05% (Z)-Jasmone; 0.01% to 0.05% Dimethyl anthranilate; 0.1% to 0.5% Methyleugenol; 8.0% to 10.0% b-Caryophyllene; 8.0% to 10.0% cis-a-Bergamotene; 8.0% to 10.0% b-Ylangene; 0.05% to 0.1% g-Elemene; 0.5% to 1.0% trans-a-Bergamotene; 0.5% to 1.0% a-Guaiene; 0.01% to 0.05% Isogermacrene D; 1.0% to 2.0% a-Humulene; 0.05% to 0.1% allo-Aromadendrene; 0.01% to 0.05% trans-Cadina- 1(6), 4-diene; 0.05% to 0.1% g- Muurolene; 1.0% to 1.5% Germacrene D; 0.1% to 0.5% b-Selinene; 0.3% to 0.6% Bicyclogermacrene; 0.3% to 0.6% a-Selinene; 0.1% to 0.2% a-Muurolene; 0.01% to 0.1% e- Amorphene; 0.1% to 0.5% b-Bisabolene; 0.1% to 0.5% g-Cadinene; 0.01% to 0.05% (3E,6E)-a-Famesene;2.0% to 3.0% d-Cadinene; 2.0% to 3.0% Myristicin; 2.0% to 3.0% trans-Calamenene; 0.01% to 0.05% trans-Cadina- 1,4-diene; 0.005% to 0.015% a-Calacorene; 0.01% to 0.05% Isocaryophyllene epoxide B; 0.1% to 0.2% Elemicin; 0.01% to 0.05% Caryophyllenyl alcohol; 0.05% to 0.1% Spathulenol; 0.1% to 0.5% Caryophyllene oxide; 0.1% to 0.5% Caryophyllene oxide isomer; 0.01% to 0.05% Viridiflorol; 0.01% to 0.05% Carotol; 0.2% to 0.5% l,2,3,4-Tetramethoxy-5-allylbenzene; 0.01% 0.05% Humulene epoxide II; 0.05% to 0.15% Junenol; 0.05% to 0.15% Guaia-6,10(14)-dien^-ol; 0.01% to 0.05% Isospathulenol; 0.05% to 0.15% x-Cadinol; 0.05% to 0.15% x-Muurolol; 0.01% to 0.1% a-Muurolol; 0.01% to 0.1% a-Cadinol; 0.01% to 0.05% (3Z)-Caryophylla-3,8(13)- dien^-ol; 0.5% to 1.0% Apiole; 0.05% to 0.15% Juniper camphor; 0.01% to 0.05% a- Sinensal; 0.01% to 0.05% (E)-Pseudoisoeugenyl 2-

Methylbutyrate;0.005% to 0.015% Epoxypseudoisoeugenyl 2-Methylbutyrate; 0.01% to 0.1% meta-Camphorene;0.01% to 0.1% (3E)-Cembrene A; 0.005% to 0.15% Citropten; 0.01% to 0.05% para-Camphorene; 0.01% to 0.05% Manool; 0.01% to 0.05% Kolavelool; 0.01% to 0.05% Osthole; 0.01% to 0.05% Cembrenol; 0.01% to 0.05% Bergapten; 0.1% to 0.2% Serratol; 0.01% to 0.1% Isoauraptene; 0.01% to 0.05% Meranzin; 0.01% to 0.05% Copalol; 0.01% to 0.05% Kolavenol; and/or 0.01% to 0.05% Pentamethoxyflavone isomer. [00035] In another embodiment, the composition comprises Citrus reticulata Blanco, Foeniculum vulgar e ssp.capillaceum var. dulce, Carum carvi, Lavandula angustifolia, Origanum marjorana l... Salvia sclarea I... Petroselinum sativum, Vanilla planifolia, Citrus reticulata Blanco and Thymus vulgaris (L.) ct Linalool.

[00036] In one embodiment, the composition comprises 1.0% to 5.0 % Citrus reticulata Blanco, 1.0% to 5.0% Foeniculum vulgare ssp.capillaceum var. dulce, 1.0% to 5.0% Carum carvi, 1.0% to 5.0% Lavandula angustifolia, 1.0% to 5.0% Origanum marjorana L., 1.0% to 2.0% Salvia sclarea L., 1.0% to 2.0% Petroselinum sativum, 1.0% to 2.0% Vanilla planifolia, 0.5% to 1.5% Citrus reticulata Blanco and/or 0.5% to 1.5% Thymus vulgaris (L.) ct Linalool.

[00037] In another embodiment, the composition comprises 2-Methyl-3-buten-2-ol; Isoamyl alcohol; 2-Methylbutanol; (3Z)-Hexenol; (2E)-Hexenol; Hexanol; Octen-3-ol; Octan-3-ol; Hexanal; (2E)-Hexenal; Heptanal; Octanal; Decanal; Hexyl acetate; Octen-3-yl acetate; Methyl hexyl ether; Octan-3-one; Sclareol; 2-Ethylfuran; Hashishene; Tricyclene; a- Thujene; a-Pinene; Camphene; a-Fenchene; Thuja-2,4(10)-diene; b-Pinene; Sabinene; Myrcene; Pseudolimonene; a-Phellandrene; A3-Carene: a-Terpinene; para-Cymene; Limonene; b-Phellandrene; (Z)-b-Ocimene; (E)-b-Ocimene; g-Terpinene; Isoterpinolene; para-Cymenene; Terpinolene; cis-Sabinene hydrate; cis-Linalool oxide (fur.); trans- Sabinene hydrate; Linalool; Hotrienol; cis-para-Menth-2-en-l-ol; cis-para-Mentha-2,8-dien-l-ol; trans- para-Menth-2-en-l-ol; Bomeol; Terpinen-4-ol; a-Terpineol; neo-Dihydrocarveol; Dihydrocarveol; trans-Carveol; cis-Carveol; Citronellal; Perillaldehyde; trans-Sabinene hydrate acetate; Linalyl acetate; Terpinen-4-yl acetate; Geranyl acetate; 1,8-Cineole; Camphor; cis-Dihydrocarvone; Carvone; Cryptone; Hodiendiol derivative; Methyl anthranilate; Dimethyl anthranilate; Methylchavicol; (E)-Anethole; Eugenol; Methyleugenol; Myristicin; Elemicin; l,2,3,4-Tetramethoxy-5-allylbenzene; Dill apiole; Apiole; Bicycloelemene; a-Copaene; b-Bourbonene; l,5-diepi-b-Bourbonene; b-Elemene; b- Caryophyllene; cis-a-Bergamotene; a-Santalene; a-Copaene; trans-a-Bergamotene; a- Humulene; 9-epi-b-Caryophyllene; (E)-b-Famesene; g-Muurolene; Germacrene D; b- Selinene; Bicyclogermacrene; (3Z,6E)^-Famesene; b-Bisabolene; (Z)-Nerolidol; (E)- Nerolidol; Spathulenol; Carotol; Guaia-6,10(14)-dien-4b-ol; x-Cadinol; Neointermedeol; (3Z)-Caryophylla-3,8(13)-dien^-ol; a-Sinensal; Isocaryophyllene epoxide B; Caryophyllene oxide; Caryophyllene oxide isomer; Benzaldehyde; para-Anisaldehyde and/or Dibutyl phthalate.

[00038] In one embodiment, the composition comprises 0.005% to 0.01% 2-Methyl-3- buten-2-ol; at most 0.005% Isoamyl alcohol; at most 0.005% 2-Methylbutanol; 0.005% to 0.015% (3Z)-Hexenol; at most 0.005% (2E)-Hexenol; 0.01% to 0.02% Hexanol; 0.01% to 0.05% Octen-3-ol; 0.1% to 0.2% Octan-3-ol; 0.005% to 0.01% Hexanal; at most 0.005% (2E)-Hexenal; 0.005% to 0.01% Heptanal; 0.02% to 0.05% Octanal; 0.02% to 0.03% Decanal; 0.03% to 0.06% Hexyl acetate; 0.07% to 0.1% Octen-3-yl acetate; 0.005% to 0.001% Methyl hexyl ether; 0.1% to 0.2% Octan-3-one; 0.01% to 0.03% Sclareol; at most 0.005% 2-Ethylfuran; 0.01% to 0.02% Hashishene; 0.005% to 0.01% Tricyclene; 0.2% to 0.5% a-Thujene; 2.0% to 5.0% a-Pinene; 0.05% to 0.1% Camphene; 0.05% to 0.1% a- Fenchene; at most 0.005% Thuja-2, 4(10)-diene; 2.0% to 5.0% b-Pinene; 2.0% to 5.0% Sabinene; 0.5% to 1.5% Myrcene; 0.1% to 0.2% Pseudolimonene; 0.1% to 0.2% a- Phellandrene; 0.01% to 0.05% A3-Carene; 0.5% to 1.5% a-Terpinene; 0.5% to 1.5% para- Cymene; 15% to 20 % Limonene; 15% to 20% b-Phellandrene; 0.1% to 0.5% (Z)-b- Ocimene; 0.15% to 0.25% (E)^-Ocimene; 5.0% to 7.0% g-Terpinene; 0.5% to 1.0% Isoterpinolene; 0.5% to 1.0% para-Cymenene; 0.5% to 1.0% Terpinolene; 0.2% to 0.5% cis- Sabinene hydrate; 0.05% to 0.1% cis-Linalool oxide (fur.); 1.0% to 2.0% trans-Sabinene hydrate; 6.0% to 10% Linalool; 0.05% to 0.1% Hotrienol; 0.1% to 0.2% cis-para-Menth-2- en-l-ol; 0.02% to 0.05% cis-para-Mentha-2,8-dien-l-ol; 0.1% to 0.2% trans-para-Menth-2- en-l-ol; 0.15% to 0.25% Bomeol; 2.0% to 4.0% Terpinen-4-ol; 0.5% to 1.5% a-Terpineol; 0.5% to 1.5% neo-Dihydrocarveol; 0.05% to 0.15% Dihydrocarveol; 0.1% to 0.2% trans- Carveol; 0.2% to 0.5% cis-Carveol; 0.005% to 0.01% Citronellal; 0.005% to 0.015% Perillaldehyde; 0.2% to 0.5% trans-Sabinene hydrate acetate; 7.0% to 10% Linalyl acetate; 0.2% to 0.5% Terpinen-4-yl acetate; 0.15% to 0.3% Geranyl acetate; 17% to 20% 1,8- Cineole; 0.1% to 0.2% Camphor; 0.2% to 0.5% cis-Dihydrocarvone; 9.0% to 13% Carvone; 0.02% to 0.05% Cryptone; 0.01% to 0.02% Hodiendiol derivative; at most 0.005% Methyl anthranilate; 2.0% to 4.0% Dimethyl anthranilate; 0.5% to 1.5% Methylchavicol; 9.0% to 13% (E)-Anethole; 0.01% to 0.05% Eugenol; 2.0% to 5.0% Methyleugenol; 3.0% to 6.0% Myristicin; 0.1% to 0.5% Elemicin; 0.5% to 1.0% l,2,3,4-Tetramethoxy-5-allylbenzene; 0.005% to 0.01% Dill apiole; 1.0% to 2.0% Apiole; 0.01% to 0.05% Bicycloelemene; 0.05% to 0.1% a-Copaene; 0.03% to 0.06% b-Bourbonene; 0.03% to 0.06% l,5-diepi^- Bourbonene; 0.05% to 0.1% b-Elemene; 0.5% to 1.5% b-Caryophyllene; 0.5% to 1.5% cis-a- Bergamotene; 0.05% to 0.1% a-Santalene; 0.01% to 0.05% a-Copaene; 0.05% to 0.1% trans- a-Bergamotene; 0.03% to 0.06% a-Humulene; 0.1% to 0.4% 9-epi^-Caryophyllene; 0.1% to 0.4% (E)^-Famesene; 0.01% to 0.04% g-Muurolene; 0.1% to 0.2% Germacrene D; 0.03% to 0.06% b-Selinene; 0.2% to 0.4% Bicyclogermacrene; 0.01% to 0.04% (3Z,6E)^-Famesene; 0.05% to 0.15% b-Bisabolene; at most 0.005% (Z)-Nerolidol; 0.01% to 0.04% (E)-Nerolidol; 0.05% to 0.15% Spathulenol; 0.05% to 0.1% Carotol; 0.005% to 0.01% Guaia-6,10(14)-dien- 4b-o1; 0.01% to 0.04% x-Cadinol; 0.01% to 0.04% Neointermedeol; 0.01% to 0.04% (3Z)- Caryophylla-3,8(13)-dien^-ol; 0.05% to 0.1% a-Sinensal; 0.01% to 0.04% Isocaryophyllene epoxide B; 0.1% to 0.2% Caryophyllene oxide; 0.1% to 0.2% Caryophyllene oxide isomer; at most 0.005% Benzaldehyde; 0.05% to 0.1% para- Anisaldehyde and/or 0.02 to 0.05% Dibutyl phthalate. [00039] In another embodiment, the composition comprises Curcuma longa L., Copaifera officinalis, Citrus limon, Citrus reticulata Blanco, Cinnamomum zeylanicum, Zingiber officinale Roscoe, Origanum marjorana L., Ocimum basilicum ct Linalool, Citrus aurantium var. bergamia, Carum carvi md/orAnethum graveolens.

[00040] In one embodiment, the composition comprises 2.0% to 4.0% Curcuma longa L., 2.0% to 4.0% Copaifera officinalis, 2.0% to 4.0% Citrus limon, 1.5% to 2.5% Citrus reticulata Blanco, 1.0% to 2.0% Cinnamomum zeylanicum, 1.0% to 2.0% Zingiber officinale Roscoe, 1.0% to 2.0% Origanum marjorana L., 0.5% to 1.5% Ocimum basilicum ct Linalool, 0.5% to 1.5% Citrus aurantium var. bergamia, 0.5% to 1.5% Carum carvi and/or 0.5% to 1.5% Anethum graveolens.

[00041] In another embodiment, the composition comprises Isovaleral; 2- Methylbutyral; Methyl 2-methylbutyrate; Ethanol; 2-Methyl-3-buten-2-ol; Heptanal; Isobomeol; Toluene; Hexanol; 2-Heptanone; Menthone; Hexanal; Benzaldehyde; 4-Hydroxy- 4-methylcyclohex-2-enone; cis-Linalool oxide (fur.); 2-Nonanone; 2-Heptanol; endo- Fenchol; trans-Carvone oxide; cis-Limonene oxide; Camphene hydrate; Tricyclene; D3- Carene; Dill ether; trans-Limonene oxide; (6R,7R)-Bisabolone; cis-para-Mentha-2,8-dien-l- ol; neo-Menthol; (Z)^-Ocimene; Citronellal; para-Cymen-8-ol; a-Gurjunene; Octanal; Terpinen-4-yl acetate; Manool; Nonanal; (E)^-Ocimene; Citropten; b-Copaene; trans- Carveol; ar-Dihydroturmerone; Methyl kolavenate; (E)-y-Bisabolene; Dimethyl anthranilate; Kolavelool; Aromadendrene; d-Elemene isomer; cis-Zingiberenol; trans-Dihydrocarvone; Dihydrocarveol; Spathulenol; (E)-a-Bisabolene; Kolavenol; cis-para-Menth-2-en-l-ol; trans- para-Mentha-2,8-dien-l-ol; (E)-Cinnamal; (E)^-Famesene; x-Cadinol; x-Muurolol; a- Terpinyl acetate; a-Cubebene; alio- Aromadendrene; (6S,7R)-Bisabolone; Junenol; Nerol; cis- Carveol; Citronellol; Benzyl acetate; Bomeol; Neryl acetate; ar-Turmerol; a-Sinensal; a- Thujene; (E)-a-Atlantone; b-Cubebene; Geranyl acetate; b-Elemene; Germacrene B; g- Muurolene; cis-Piperitol; cis-Dihydrocarvone; (E)-Cinnamyl acetate; a-Phellandrene; Pseudolimonene; Camphor; trans-para-Menth-2-en-l-ol; cis-Sabinene hydrate; Caryophyllene oxide; Caryophyllene oxide isomer; 6-Methyl-5-hepten-2-one; trans- Zingiberenol; Bomyl acetate; Safrole; Terpinolene; trans-Linalool oxide (fur.); para- Cymenene; d-Cadinene; a-Terpineol; Bicyclogermacrene; Geranial; Perillaldehyde; Eugenyl acetate; a-Terpinene; Benzyl benzoate; Myrcene; trans-a-Bergamotene; a-Copaene; a- Pinene; Germacrene D; Camphene; a-Fenchene; a-Humulene; trans-Sabinene hydrate; Terpinen-4-ol; ar-Curcumene; b-Selinene; b-Sesquiphellandrene; Linalool; (3E,6E)-a- Famesene; g-Cadinene; b-Bisabolene; b-Curcumene; a-Zingiberene; a-Muurolene; Linalyl acetate; Geraniol; Methylchavicol; Sabinene; b-Pinene; b-Turmerone; g-Terpinene; Eugenol; Carvone; ar-Turmerone; a-Turmerone; b-Caryophyllene; cis-a-Bergamotene; para-Cymene; Limonene and/or 1,8-Cineole.

[00042] In one embodiment, the composition comprises at most 0.005% Isovaleral; at most 0.005% 2-Methylbutyral; at most 0.005% Methyl 2-methylbutyrate; at most 0.005% Ethanol; at most 0.005% 2-Methyl-3-buten-2-ol; Heptanal; at most 0.005% Isobomeol; at most 0.005% Toluene; at most 0.005% Hexanol; at most 0.005% 2-Heptanone; at most 0.005% Menthone; at most 0.005% Hexanal; 0.005% to 0.01% Benzaldehyde; 0.005% to 0.01% 4-Hydroxy-4-methylcyclohex-2-enone; 0.005% to 0.015% cis-Linalool oxide (fur.); 0.005% to 0.015% 2-Nonanone; 0.005% to 0.015% 2-Heptanol; 0.005% to 0.015% endo- Fenchol; 0.005% to 0.015% trans-Carvone oxide; 0.005% to 0.015% cis-Limonene oxide; 0.01% to 0.02% Camphene hydrate; 0.015% to 0.03% Tricyclene; 0.015% to 0.03% D3- Carene; 0.015% to 0.03% Dill ether; 0.015% to 0.03% trans-Limonene oxide; 0.015% to 0.03% (6R,7R)-Bisabolone; 0.015% to 0.03% cis-para-Mentha-2,8-dien-l-ol; 0.02% to 0.04% neo-Menthol; 0.02% to 0.04% (Z)^-Ocimene; 0.02% to 0.04% Citronellal; 0.02% to 0.04% para-Cymen-8-ol; 0.02% to 0.04% a-Gurjunene; Octanal; 0.02% to 0.04% Terpinen- 4-yl acetate; 0.03% to 0.05% Manool; 0.03% to 0.05% Nonanal; 0.03% to 0.05% (E)-b- Ocimene; 0.03% to 0.05% Citropten; 0.05% to 0.1% b-Copaene; 0.05% to 0.1% trans- Carveol; 0.05% to 0.1% ar-Dihydroturmerone; 0.05% to 0.1% Methyl kolavenate; 0.05% to 0.1% (E)-y-Bisabolene; 0.05% to 0.1% Dimethyl anthranilate; 0.05% to 0.1% Kolavelool; 0.05% to 0.1% Aromadendrene; 0.05% to 0.1% d-Elemene isomer; 0.05% to 0.15% cis- Zingiberenol; 0.05% to 0.15% trans-Dihydrocarvone; 0.05% to 0.15% Dihydrocarveol; 0.05% to 0.15% Spathulenol; 0.05% to 0.15% (E)-a-Bisabolene; 0.05% to 0.15% Kolavenol; 0.05% to 0.15% cis-para-Menth-2-en-l-ol; 0.05% to 0.15% trans-para-Mentha-2,8-dien-l-ol; 0.05% to 0.15% (E)-Cinnamal; 0.1% to 0.2% (E)^-Famesene; 0.1% to 0.2% x-Cadinol; 0.1% to 0.2% x-Muurolol; 0.1% to 0.2% a-Terpinyl acetate; 0.1% to 0.2% a-Cubebene; 0.1% to 0.2% allo-Aromadendrene; 0.1% to 0.2% (6S,7R)-Bisabolone; 0.1% to 0.2% Junenol; 0.1% to 0.2% Nerol; 0.1% to 0.2% cis-Carveol; 0.1% to 0.2% Citronellol; 0.1% to 0.2% Benzyl acetate; 0.1% to 0.2% Bomeol; 0.15% to 0.3% Neryl acetate; 0.15% to 0.3% ar- Turmerol; 0.15% to 0.3% a-Sinensal; 0.15% to 0.3% a-Thujene; 0.15% to 0.3% (E)-a- Atlantone; 0.15% to 0.3% b-Cubebene; 0.15% to 0.3% Geranyl acetate; 0.15% to 0.3% b- Elemene; 0.15% to 0.3% Germacrene B; 0.15% to 0.3% g-Muurolene; 0.15% to 0.3% cis- Piperitol; 0.15% to 0.3% cis-Dihydrocarvone; 0.25% to 0.35% (E)-Cinnamyl acetate; 0.25% to 0.35% a-Phellandrene; 0.25% to 0.35% Pseudolimonene; 0.25% to 0.35% Camphor; 0.25% to 0.35% trans-para-Menth-2-en-l-ol; 0.25% to 0.35% cis-Sabinene hydrate; 0.25% to 0.35% Caryophyllene oxide; 0.25% to 0.35% Caryophyllene oxide isomer; 0.25% to 0.35% 6-Methyl-5-hepten-2-one; 0.25% to 0.35% trans-Zingiberenol; 0.35% to 0.5% Bomyl acetate; 0.35% to 0.5% Safrole; 0.35% to 0.5% Terpinolene; 0.35% to 0.5% trans-Linalool oxide (fur.); 0.35% to 0.5% para-Cymenene; 0.35% to 0.5% d-Cadinene; 0.35% to 0.5% a- Terpineol; 0.35% to 0.5% Bicyclogermacrene; 0.5% to 1.0% Geranial; 0.5% to 1.0% Perillaldehyde; 0.5% to 1.0% Eugenyl acetate; 0.5% to 1.0% a-Terpinene; 0.5% to 1.0% Benzyl benzoate; 0.5% to 1.0% Myrcene; 0.5% to 1.0% trans-a-Bergamotene; 0.5% to 1.0% a-Copaene; 0.5% to 1.0% a-Pinene; 0.5% to 1.0% Germacrene D; 0.5% to 1.5% Camphene; 0.5% to 1.5% a-Fenchene; 0.5% to 1.5% a-Humulene; 0.5% to 1.5% trans-Sabinene hydrate; 0.5% to 1.5% Terpinen-4-ol; 0.5% to 1.5% ar-Curcumene; 0.5% to 1.5% b-Selinene; 1.0% to 2.0% b-Sesquiphellandrene; 1.0% to 2.0% Linalool; 1.0% to 2.0% (3E,6E)-a-Famesene; g- Cadinene; 1.0% to 2.0% b-Bisabolene; 1.0% to 2.0% b-Curcumene; 1.0% to 2.0% a- Zingiberene; 1.0% to 2.0% a-Muurolene; 1.5% to 2.5% Linalyl acetate; 1.5% to 2.5% Geraniol; 1.5% to 2.5% Methylchavicol; 2.5% to 3.5% Sabinene; 2.5% to 3.5% b-Pinene; 2.5% to 3.5% b-Turmerone; 3.0% to 5.0% g-Terpinene; 4.0% to 6.0% Eugenol; 5.0% to 7.0% Carvone; 7.0% to 10% ar-Turmerone; 7.0% to 10% a-Turmerone; 7.0% to 10% b- Caryophyllene; 7.0% to 10% cis-a-Bergamotene; 20% to 25% para-Cymene; 20% to 25% Limonene and/or 20% to 25% 1,8-Cineole.

[00043] In another embodiment, the composition comprises Anthemis nobilis, Piper methysticum, Lavandula angustifolia, Cymbopogon citratus, Citrus aurantium var. bergamia, Origanum marjorana L., Citrus aurantium var.amara L. and/or Santalum Spicatum.

[00044] In one embodiment, the composition comprises 3.0% to 6.0% Anthemis nobilis, 3.0% to 6.0% Piper methysticum, 2.0% to 5.0% Lavandula angustifolia, 2.0% to 5.0% Cymbopogon citratus, 1.0% to 4.0% Citrus aurantium var. bergamia, 0.5% to 3.0% Origanum marjorana L., 0.5% to 3.0% Citrus aurantium var.amara L. and/or 0.5% to 3.0% Santalum Spicatum.

[00045] In another embodiment, the composition comprises 2-Methylbutyral; Toluene; Hexan-3-ol; Butyl acetate; Propyl 2-methylbutyrate; Sclareoloxide; 2-Methylbutanol; 2,4- Dimethyl-3-pentanone; Isoamyl alcohol; (2E)-Hexenal; Isovaleral; 3-Methylpentanol; Benzaldehyde; Ethanol; Methallyl isobutyrate; 2-Methyl-3-buten-2-ol; (2E)-Hexenol; 2- Methylbutyl methacrylate; Isoamyl methacrylate; Isobutyl methacrylate; Methyl kolavenate; Isopulegol isomer; Methyl hexyl ether; a-Pinene oxide analog; l,5-diepi^-Bourbonene; a- Phellandrene; Isoamyl acetate; a-Ylangene; Isobutyl isobutyrate; Tricyclene; a-Terpinene; Manool; Hodiendiol derivative; (3Z)-Hexenol; Hexanol; Aromadendrene; Cyclosativene I; cis-Sabinene hydrate; allo-Ocimene; Geranyl formate; 4-Nonanone; Octan-3-yl acetate; Kolavelool; 3-Methylpentyl methacrylate; b-Bourbonene; Grandiflorone; Cyclosativene II; Cryptone; trans-Carveol; Linalyl formate; 3-Methylpentyl angelate; Copalol; Kolavenol; a- Thujene; Methyl benzoate; Hexyl tiglate; Octanal; cis-Dehydroxylinalool oxide; Octen-3-ol; 3-Methylpentyl acetate; cis-Linalool oxide (fur.); A3-Carene; Palustrol; Octan-3-ol; Decanal; Camphene; a-Fenchene; Sclareol; neoiso-Isopulegol; d-Elemene isomer; a-Gurjunene; Isocaryophyllene; b-Copaene; epi-b-Santalene; Isobutyl angelate; Methallyl angelate; Muurola-4, 11 -diene; Benzyl salicylate; trans-Pinocarveol; allo-Aromadendrene; cis-Cadina- 1(6), 4-diene; (2E,6E)-Famesyl acetate; Hexyl butyrate; Myrtenol; Spathulenol; (Z)-erί-b- Santalol; para-Cymene; g-Terpinene; a-Muurolene; (6R,7R)-Bisabolone; Hexyl acetate; para- Methylanisole; a-Cubebene; 8-Hydroxymenthol; Terpinolene; para-Cymenene; trans- Linalool oxide (fur.); b-Elemene; Octen-3-yl acetate; Benzyl acetate; a-Cadinene; Flavesone; Selina-3, 7(1 l)-diene; Caryophyllenyl alcohol; (E)-Nerolidol; (Z)-a-trans-Bergamotol; trans- Cadina- 1,4-diene; Ledol; Eudesm-5-en-ll-ol analog; Nerol; (2E,6E)-Famesol; (Z)-Nuciferol; Bomeol; (Z)-Lanceol; Isoleptospermone; Benzyl benzoate; Caryophyllene oxide; Caryophyllene oxide isomer; Viridiflorol; Octan-3-one; 6-Methyl-5-hepten-2-one; a- Zingiberene; g-Muurolene; g-Curcumene; Leptospermone; Isopulegol; neo-Isopulegol; Citronellol; Sabinene; b-Pinene; trans-a-Bergamotene; x-Cadinol; x-Muurolol; Neryl acetate; Drimenol; b-Selinene; ar-Curcumene; (Z)^-Santalol; a-Selinene; (E)-b-Famesene; Lavandulyl acetate; a-Copaene; Myrcene; trans-Dehydroxylinalool oxide; (E)-b-Ocimene; cis-Zingiberenol; lO-epi-y-Eudesmol; a-Humulene; (Z)-b-Ocimene; Terpinen-4-ol; 7-epi-a- Eudesmol; g-Eudesmol; (Z)-a-Santalol; b-Bisabolene; (3E,6E)-a-Famesene; g-Cadinene; Geranyl acetate; b-Cubebene; a-Terpineol; a-Elemol; b-Sesquiphellandrene; d-Cadinene; Zonarene; Germacrene D; Neral; Geranial; a-Pinene; b-Eudesmol; Valerianol; a-Eudesmol; Citronellal; iso-Isopulegol; Pinocarvone; 2-Methylbutyl angelate; Isoamyl angelate; b- Caryophyllene; cis-a-Bergamotene; a-Santalene; Limonene; 1,8-Cineole; Linalool; Nonanal; Linalyl acetate and/or Geraniol.

[00046] In one embodiment, the composition comprises at most 0.005% 2- Methylbutyral; at most 0.005% Toluene; at most 0.005% Hexan-3-ol; at most 0.005% Butyl acetate; at most 0.005% Propyl 2-methylbutyrate; at most 0.005% Sclareoloxide; at most 0.005% 2-Methylbutanol; at most 0.005% 2,4-Dimethyl-3-pentanone; at most 0.005% Isoamyl alcohol; at most 0.005% (2E)-Hexenal; at most 0.005% Isovaleral; at most 0.005% 3-Methylpentanol; at most 0.005% Benzaldehyde; 0.005% to 0.01% Ethanol; 0.005% to 0.01% Methallyl isobutyrate; 0.005% to 0.01% 2-Methyl-3-buten-2-ol; 0.005% to 0.01% (2E)-Hexenol; 0.005% to 0.01% 2-Methylbutyl methacrylate; 0.005% to 0.01% Isoamyl methacrylate; 0.005% to 0.01% Isobutyl methacrylate; 0.005% to 0.01% Methyl kolavenate; 0.01% to 0.02% Isopulegol isomer; 0.01% to 0.02% Methyl hexyl ether; 0.01% to 0.02% a- Pinene oxide analog; 0.01% to 0.02% l,5-diepi^-Bourbonene; 0.01% to 0.02% a- Phellandrene; 0.01% to 0.02% Isoamyl acetate; 0.01% to 0.02% a-Ylangene; 0.015% to 0.03% Isobutyl isobutyrate; 0.015% to 0.03% Tricyclene; 0.015% to 0.03% a-Terpinene; 0.015% to 0.03% Manool; 0.015% to 0.03% Hodiendiol derivative; 0.015% to 0.03% (3Z)- Hexenol; 0.015% to 0.03% Hexanol; 0.015% to 0.03% Aromadendrene; 0.015% to 0.03% Cyclosativene I; 0.015% to 0.03% cis-Sabinene hydrate; 0.015% to 0.03% allo-Ocimene; 0.015% to 0.03% Geranyl formate; 0.02% to 0.05% 4-Nonanone; 0.02% to 0.05% Octan-3-yl acetate; 0.02% to 0.05% Kolavelool; 0.02% to 0.05% 3-Methylpentyl methacrylate; 0.02% to 0.05% b-Bourbonene; 0.02% to 0.05% Grandiflorone; 0.02% to 0.05% Cyclosativene II; 0.02% to 0.05% Cryptone; 0.02% to 0.05% trans-Carveol; 0.02% to 0.05% Linalyl formate; 0.02% to 0.05% 3-Methylpentyl angelate; 0.02% to 0.05% Copalol; 0.02% to 0.05% Kolavenol; 0.04% to 0.1% a-Thujene; 0.04% to 0.1% Methyl benzoate; 0.04% to 0.1% Hexyl tiglate; 0.04% to 0.1% Octanal; 0.04% to 0.1% cis-Dehydroxylinalool oxide; 0.04% to 0.1% Octen-3-ol; 0.04% to 0.1% 3-Methylpentyl acetate; 0.04% to 0.1% cis-Linalool oxide (fur.); 0.04% to 0.1% A3-Carene; 0.04% to 0.1% Palustrol; 0.04% to 0.1% Octan-3-ol; 0.04% to 0.1% Decanal; 0.04% to 0.1% Camphene; 0.04% to 0.1% a-Fenchene; 0.04% to 0.1% Sclareol; 0.04% to 0.1% neoiso-Isopulegol; 0.05% to 0.15% d-Elemene isomer; 0.05% to 0.15% a-Gurjunene; 0.05% to 0.15% Isocaryophyllene; 0.05% to 0.15% b-Copaene; 0.05% to 0.15% epi^-Santalene; 0.05% to 0.15% Isobutyl angelate; 0.05% to 0.15% Methallyl angelate; 0.05% to 0.15% Muurola-4, 11 -diene; 0.05% to 0.15% Benzyl salicylate; 0.05% to 0.15% trans-Pinocarveol; 0.05% to 0.15% allo-Aromadendrene; 0.05% to 0.15% cis-Cadina- 1(6), 4-diene; 0.05% to 0.15% (2E,6E)-Famesyl acetate; 0.05% to 0.15% Hexyl butyrate; 0.05% to 0.15% Myrtenol; 0.05% to 0.15% Spathulenol; 0.05% to 0.15% (Z)-epi^-Santalol; 0.1% to 0.2% para-Cymene; 0.1% to 0.2% g-Terpinene; 0.1% to 0.2% a-Muurolene; 0.1% to 0.2% (6R,7R)-Bisabolone; 0.1% to 0.2% Hexyl acetate; 0.1% to 0.2% para-Methylanisole; 0.1% to 0.2% a-Cubebene; 0.1% to 0.2% 8-Hydroxymenthol; 0.1% to 0.2% Terpinolene; 0.1% to 0.2% para-Cymenene; 0.1% to 0.2% trans-Linalool oxide (fur.); 0.1% to 0.2% b- Elemene; 0.1% to 0.2% Octen-3-yl acetate; 0.1% to 0.2% Benzyl acetate; 0.15% to 0.3% a- Cadinene; 0.15% to 0.3% Flavesone; 0.15% to 0.3% Selina-3, 7(1 l)-diene; 0.15% to 0.3% Caryophyllenyl alcohol; 0.15% to 0.3% (E)-Nerolidol; 0.15% to 0.3% (Z)-a-trans- Bergamotol; 0.15% to 0.3% trans-Cadina- 1,4-diene; 0.15% to 0.3% Ledol; 0.15% to 0.3% Eudesm-5-en-ll-ol analog; 0.15% to 0.3% Nerol; 0.15% to 0.3% (2E,6E)-Famesol; 0.15% to 0.3% (Z)-Nuciferol; 0.15% to 0.3% Bomeol; 0.15% to 0.3% (Z)-Lanceol; 0.15% to 0.3% Isoleptospermone; 0.15% to 0.3% Benzyl benzoate; 0.15% to 0.3% Caryophyllene oxide; 0.15% to 0.3% Caryophyllene oxide isomer; 0.15% to 0.3% Viridiflorol; 0.25% to 0.5% Octan-3-one; 0.25% to 0.5% 6-Methyl-5-hepten-2-one; 0.25% to 0.5% a-Zingiberene; 0.25% to 0.5% g-Muurolene; 0.25% to 0.5% g-Curcumene; 0.25% to 0.5% Leptospermone; 0.25% to 0.5% Isopulegol; 0.25% to 0.5% neo-Isopulegol; 0.25% to 0.5% Citronellol; 0.25% to 0.5% Sabinene; 0.25% to 0.5% b-Pinene; 0.25% to 0.5% trans-a-Bergamotene; 0.25% to 0.5% x-Cadinol; 0.25% to 0.5% x-Muurolol; 0.25% to 0.5% Neryl acetate; 0.25% to 0.5% Drimenol; 0.25% to 0.5% b-Selinene; 0.25% to 0.5% ar-Curcumene; 0.4% to 1.0% (Z)-b- Santalol; 0.4% to 1.0% a-Selinene; 0.4% to 1.0% (E)^-Famesene; 0.4% to 1.0% Lavandulyl acetate; 0.4% to 1.0% a-Copaene; 0.4% to 1.0% Myrcene; 0.4% to 1.0% trans- Dehydroxylinalool oxide; 0.4% to 1.0% (E)^-Ocimene; 0.4% to 1.0% cis-Zingiberenol; 0.4% to 1.0% lO-epi-y-Eudesmol; 0.4% to 1.0% a-Humulene; 0.4% to 1.0% (Z)^-Ocimene; 0.4% to 1.0% Terpinen-4-ol; 0.4% to 1.0% 7-epi-a-Eudesmol; 0.4% to 1.0% g-Eudesmol; 0.5% to 1.5% (Z)-a-Santalol; 0.5% to 1.5% b-Bisabolene; 0.5% to 1.5% (3E,6E)-a- Famesene; 0.5% to 1.5% g-Cadinene; 0.5% to 1.5% Geranyl acetate; 0.5% to 1.5% b- Cubebene; 0.5% to 1.5% a-Terpineol; 0.5% to 1.5% a-Elemol; 0.5% to 1.5% b- Sesquiphellandrene; 0.5% to 1.5% d-Cadinene; 0.5% to 1.5% Zonarene; 1.0% to 2.0% Germacrene D; 1.0% to 2.0% Neral; 1.5% to 3.0% Geranial; 2.0% to 5.0% a-Pinene; 2.0% to 5.0% b-Eudesmol; 2.0% to 5.0% Valerianol; 2.0% to 5.0% a-Eudesmol; 4.0% to 6.0% Citronellal; 4.0% to 6.0% iso-Isopulegol; 4.0% to 6.0% Pinocarvone; 4.0% to 6.0% 2- Methylbutyl angelate; 4.0% to 6.0% Isoamyl angelate; 5.0% to 8.0% b-Caryophyllene; 5.0% to 8.0% cis-a-Bergamotene; 5.0% to 8.0% a-Santalene; 12% to 16% Limonene; 12% to 16% 1,8-Cineole; 12% to 16% Linalool; 12% to 16% Nonanal; 13% to 17% Linalyl acetate and/or 13% to 17% Geraniol.

[00047] In another embodiment, the composition comprises Copaifera officinalis, Citrus aurantium var. amara, Mentha x piperita L, Anethum graveolens, Citrus sinensis (L.) Osbeck, Citrus limon, Petroselinum sativum, Piper nigrum, Zingiber officinale Roscoe, Hyssopus officinalis, Carum carvi, Origanum vulgar e L., Mentha spicata L., Salvia sclarea L., Citrus aurantium var. bergamia, Pelargonium graveolens var roseum, Foeniculum vulgar e ssp.capillaceum var. dulce, Ocimum basilicum ct Linalool, Rosmarinus officinalis (L.) ct cineole and/or Salvia officinalis L.. [00048] In one embodiment, the composition comprises 1.0% to 4.0% Copaifera officinalis, 1.0% to 4.0% Citrus aurantium var. amara, 1.0% to 4.0% Mentha x piperita L, 1.0% to 4.0 % Anethum graveolens, 0.5% to 2.0% Citrus sinensis (L.) Osbeck, 0.5% to 2.0% Citrus limon, 0.5% to 2.0% Petroselinum sativum, 0.5% to 2.0% Piper nigrum, 0.5% to 2.0% Zingiber officinale Roscoe, 0.5% to 2.0% Hyssopus officinalis, 0.5% to 1.5% Carum carvi, 0.5% to 1.5% Origanum vulgare L., 0.5% to 1.5% Mentha spicata L., 0.5% to 1.5% Salvia sclarea L., 0.5% to 1.5% Citrus aurantium var. bergamia, 0.5% to 1.5% Pelargonium graveolens var roseum, 0.3% to 0.7% Foeniculum vulgare ssp.capillaceum var. dulce, 0.2% to 0.5% Ocimum basilicum ct Linalool, 0.1% to 0.4% Rosmarinus officinalis (L.) ct cineole and/or 0.1% to 0.4% Salvia officinalis L..

[00049] In another embodiment, the composition comprises 2-Methylbutanol; Isoamyl alcohol; Toluene; Isovaleral; 2-Methylbutyral; trans-2,5-Diethyltetrahydrofuran; Isoterpinolene; (3Z)-Hexenol; Hashishene; Octan-3-yl acetate; Hexanol; Octanol; trans-Rose oxide; Meranzin; Kolavenol; iperitenone; Caryophylladienol II; a-Calacorene; cis-Linalool oxide (fur.); Bergapten; Osthole; Octyl acetate; cis-Rose oxide; Octen-3-ol; Octanal; Isocaryophyllene; Juniper camphor; Nootkatone; Kolavelool; a-Gurjunene; Globulol; Verbenone; Viridiflorol; Cyperene; Manool; Dill ether; a-Cadinene; Camphene hydrate; (E)- Foeniculin; Spathulenol; meta-Camphorene; Tricyclene; cis-Limonene oxide; Octan-3-ol; neo-Menthyl acetate; Sclareol; Decanal; a-Thujone; b-Eudesmol; Guaia-6.1 ()( 14)-dien-4 -ol: a-Cadinol; trans-Carveol; (E)-a-Bisabolene; Geranyl tiglate; Carotol; cis-para-Menth-2-en-l- ol; trans-para-Mentha-2,8-dien-l-ol; trans-Limonene oxide; cis-para-Mentha-2,8-dien-l-ol; trans-Pinocarveol; a-Guaiene; a-Muurolol; (Z)^-Ocimene; Citronellol; cis-Carveol; Caryophyllenyl alcohol; (E)-y-Bisabolene; x-Muurolol; x-Cadinol; b-Copaene; a-Muurolene; Junenol; b-Thujone; a-Terpinene; (E)^-Ocimene; Citronellal; Pinocamphone; allo- Aromadendrene; d-Terpineol; Isopinocamphone; Citropten; Isomenthyl acetate; lO-epi-g- Eudesmol; Fenchone; a-Cubebene; (E)-b-Famesene; Neryl acetate; trans-Dihydrocarvone; trans-Isopiperitenol; 6,9-Guaiadiene; Bomeol; cis-Sabinene hydrate; Terpinolene; trans- Linalool oxide (fur.); para-Cymenene; b-Bourbonene; d-Elemene; Isomenthol; Piperitone; a- Phellandrene; Pseudolimonene; g-Muurolene; b-Elemene; Thymol; Geranyl acetate; b- Cubebene; Elemicin; a-Terpineol; Octan-3-one; 6-Methyl-5-hepten-2-one; g-Cadinene; Citronellyl formate; a-Thujene; Viridiflorene; Bicyclogermacrene; a-Selinene; Geranial; Menthyl acetate; neo-Menthol; neoiso-Menthol; l,2,3,4-Tetramethoxy-5-allylbenzene; Diethyl phthalate; Caryophyllene oxide isomer; Caryophyllene oxide; Camphor; (3E,6E)-a- Famesene; b-Bisabolene; trans-a-Bergamotene; a-Copaene; b-Selinene; ar-Curcumene; Isomenthone; Menthofuran; Apiole; A3-Carene: Germacrene D; a-Humulene; para-Cymene; a-Zingiberene; Camphene; a-Fenchene; 3-Methylcyclohexanone; g-Terpinene; Methylchavicol; cis-Dihydrocarvone; Myrcene; Pulegone; Menthone; (E)-Anethole; a- Pinene; Carvacrol; Geraniol; cis-Myrtanol; Linalyl acetate; d-Cadinene; Myristicin; Sabinene; b-Pinene; Menthol; Terpinen-4-ol; Linalool; b-Caryophyllene; cis-a-Bergamotene; Carvone; Limonene and/or 1,8-Cineole.

[00050] In one embodiment, the composition comprises at most 0.005% 2- Methylbutanol; at most 0.005% Isoamyl alcohol; at most 0.005% Toluene; at most 0.005% Isovaleral; at most 0.005% 2-Methylbutyral; at most 0.005% trans-2,5- Diethyltetrahydrofuran; at most 0.005% Isoterpinolene; 0.005% to 0.01% (3Z)-Hexenol; 0.005% to 0.01% Hashishene; 0.005% to 0.01% Octan-3-yl acetate; 0.005% to 0.01% Hexanol; 0.005% to 0.015% Octanol; 0.01% to 0.02% trans-Rose oxide; 0.01% to 0.02% Meranzin; 0.01% to 0.02% Kolavenol; 0.01% to 0.02% iperitenone; 0.01% to 0.02% Caryophylladienol II; 0.015% to 0.03% a-Calacorene; 0.015% to 0.03% cis-Linalool oxide (fur.); 0.015% to 0.03% Bergapten; 0.015% to 0.03% Osthole; 0.015% to 0.03% Octyl acetate; 0.015% to 0.03% cis-Rose oxide; 0.015% to 0.03% Octen-3-ol; 0.015% to 0.03% Octanal; 0.015% to 0.03% Isocaryophyllene; 0.015% to 0.03% Juniper camphor; 0.015% to 0.03% Nootkatone; 0.015% to 0.03% Kolavelool; 0.02% to 0.05% a-Gurjunene; 0.02% to 0.05% Globulol; 0.02% to 0.05% Verbenone; 0.02% to 0.05% Viridiflorol; 0.02% to 0.05% Cyperene; 0.02% to 0.05% Manool; 0.02% to 0.05% Dill ether; 0.02% to 0.05% a-Cadinene; 0.02% to 0.05% Camphene hydrate; 0.02% to 0.05% (E)-Foeniculin; 0.02% to 0.05% Spathulenol; 0.02% to 0.05% meta-Camphorene; 0.02% to 0.05% Tricyclene; 0.02% to 0.05% cis-Limonene oxide; 0.02% to 0.05% Octan-3-ol; 0.02% to 0.05% neo-Menthyl acetate; 0.02% to 0.05% Sclareol; 0.03% to 0.1% Decanal; 0.03% to 0.1% a-Thujone; 0.03% to 0.1% b-Eudesmol; 0.03% to 0.1% Guaia-6,10(14)-dien^-ol; 0.03% to 0.1% a-Cadinol; 0.03% to 0.1% trans-Carveol; 0.03% to 0.1% (E)-a-Bisabolene; 0.03% to 0.1% Geranyl tiglate; 0.03% to 0.1% Carotol; cis-para-Menth-2-en-l-ol; 0.03% to 0.1% trans-para-Mentha- 2,8-dien-l-ol; 0.03% to 0.1% trans-Limonene oxide; 0.03% to 0.1% cis-para-Mentha-2,8- dien-l-ol; 0.03% to 0.1% trans-Pinocarveol; 0.03% to 0.1% a-Guaiene; 0.05% to 0.1% a- Muurolol; 0.05% to 0.1% (Z)^-Ocimene; 0.05% to 0.1% Citronellol; 0.05% to 0.1% cis- Carveol; 0.05% to 0.1% Caryophyllenyl alcohol; 0.05% to 0.1% (E)-y-Bisabolene; 0.05% to 0.1% x-Muurolol; 0.05% to 0.1% x-Cadinol; 0.05% to 0.1% b-Copaene; 0.05% to 0.1% a- Muurolene; 0.05% to 0.1% Junenol; 0.05% to 0.1% b-Thujone; 0.05% to 0.1% a-Terpinene; 0.05% to 0.1% (E)^-Ocimene; 0.05% to 0.1% Citronellal; 0.05% to 0.1% Pinocamphone; 0.05% to 0.1% allo-Aromadendrene; 0.05% to 0.1% d-Terpineol; 0.05% to 0.1% Isopinocamphone; 0.07% to 0.15% Citropten; 0.07% to 0.15% Isomenthyl acetate; 0.07% to 0.15% lO-epi-y-Eudesmol; 0.07% to 0.15% Fenchone; 0.07% to 0.15% a-Cubebene; 0.07% to 0.15% (E)- -Famesene; 0.07% to 0.15% Neryl acetate; 0.07% to 0.15% trans- Dihydrocarvone; 0.07% to 0.15% trans-Isopiperitenol; 0.07% to 0.15% 6,9-Guaiadiene; 0.07% to 0.15% Bomeol; 0.07% to 0.15% cis-Sabinene hydrate; 0.07% to 0.15% Terpinolene; 0.07% to 0.15% trans-Linalool oxide (fur.); 0.07% to 0.15% para-Cymenene; 0.07% to 0.15% b-Bourbonene; 0.07% to 0.15% d-Elemene; 0.07% to 0.15% Isomenthol; 0.07% to 0.15% Piperitone; 0.1% to 0.2% a-Phellandrene; 0.1% to 0.2% Pseudolimonene; 0.1% to 0.2% g-Muurolene; 0.1% to 0.2% b-Elemene; 0.1% to 0.2% Thymol; 0.15% to 0.3% Geranyl acetate; 0.15% to 0.3% b-Cubebene; 0.15% to 0.3% Elemicin; 0.15% to 0.3% a- Terpineol; 0.15% to 0.3% Octan-3-one; 0.15% to 0.3% 6-Methyl-5-hepten-2-one; 0.15% to 0.3% g-Cadinene; 0.25% to 0.5% Citronellyl formate; 0.25% to 0.5% a-Thujene; 0.25% to 0.5% Viridiflorene; 0.25% to 0.5% Bicyclogermacrene; 0.25% to 0.5% a-Selinene; 0.25% to 0.5% Geranial; 0.25% to 0.5% Menthyl acetate; 0.25% to 0.5% neo-Menthol; 0.25% to 0.5% neoiso-Menthol; 0.25% to 0.5% l,2,3,4-Tetramethoxy-5-allylbenzene; 0.25% to 0.5% Diethyl phthalate; 0.3% to 1.0% Caryophyllene oxide isomer; 0.3% to 1.0% Caryophyllene oxide; 0.3% to 1.0% Camphor; 0.3% to 1.0% (3E,6E)-a-Famesene; 0.3% to 1.0% b- Bisabolene; 0.5% to 1.0% trans-a-Bergamotene; 0.5% to 1.0% a-Copaene; 0.5% to 1.0% b- Selinene; 0.5% to 1.0% ar-Curcumene; 0.5% to 1.0% Isomenthone; 0.5% to 1.0% Menthofuran; 0.5% to 1.0% Apiole; 0.5% to 1.0% A3-Carene; 0.5% to 1.0% Germacrene D; 0.5% to 1.0% a-Humulene; 0.7% to 1.5% para-Cymene; 0.7% to 1.5% a-Zingiberene; 0.7% to 1.5% Camphene; 0.7% to 1.5% a-Fenchene; 0.7% to 1.5% 3-Methylcyclohexanone; 0.7% to 1.5% g-Terpinene; 0.7% to 1.5% Methylchavicol; 0.7% to 1.5% cis-Dihydrocarvone; 0.7% to 1.5% Myrcene; 0.7% to 1.5% Pulegone; 1.5% to 3.0% Menthone; 1.5% to 3.0% (E)- Anethole; 2.0% to 5.0% a-Pinene; 2.0% to 5.0% Carvacrol; 2.0% to 5.0% Geraniol; 2.0% to 5.0% cis-Myrtanol; 2.0% to 5.0% Linalyl acetate; 2.0% to 5.0% d-Cadinene; 2.0% to 5.0% Myristicin; 2.0% to 5.0% Sabinene; 2.0% to 5.0% b-Pinene; 2.0% to 5.0% Menthol; 2.0% to 5.0% Terpinen-4-ol; 2.0% to 5.0% Linalool; 5.0% to 9.0% b-Caryophyllene; 5.0% to 9.0% cis-a-Bergamotene; 5.0% to 9.0% Carvone; 28% to 33% Limonene and/or 28% to 33% 1,8- Cineole.

[00051] In another embodiment, the composition comprises Boswellia carterii, Rosmarinus officinalis (L.) ct cineole, Citrus limon, Citrus aurantium var. amara, Cananga odorata var. Genuina, Citrus sinensis (1.) osbeck, Salvia sclarea L., Anethum graveolens, Salvia officinalis I... Piper nigrum, Mentha spicata I... Melaleuca alternifolia and/or Eucalyptus radiate.

[00052] In one embodiment, the composition comprises 1.0% to 4.0% Boswellia carterii, 1.0% to 4.0% Rosmarinus officinalis (L.) ct cineole, 0.5% to 2.5% Citrus limon, 0.5% to 2.5% Citrus aurantium var. amara, 0.5% to 2.5% Cananga odorata var. Genuina, 0.5% to 2.5% Citrus sinensis (1.) osbeck, 0.5% to 2.5% Salvia sclarea L., 0.5% to 2.5% Anethum graveolens, 0.5% to 2.5% Salvia officinalis L., 0.5% to 2.5% Piper nigrum, 0.5% to 2.5% Mentha spicata L., 0.5% to 2.5% Melaleuca alternifolia and/or 0.1% to 1.5% Eucalyptus radiate.

[00053] In another embodiment, the composition comprises Ethanol; 2-Methylpentane; Isovaleral; Isoamyl alcohol; 3-Methylpentane; 2-Methyl-3-buten-2-ol; Toluene; (3Z)- Hexenol; Cyclohexane; 5-Methylfurfural; Hashishene; meta-Cymene; Camphenilone; Styrene; 3-Methylcyclopentane; Rosefuran; Hexane; trans-Carveol; Sclareol; trans-Rose oxide; cis-para-Mentha-2,8-dien-l-ol; Globulol; cis-Sabinene hydrate; Carvotanacetone; Thuja-2,4(10)-diene; Limona ketone; Octanal; cis-Linalool oxide (fur.); Octyl acetate; 4,5- diepi-Aristolochene; Verbenone; Neryl propionate; Isogeranial; a-Ylangene; Viridiflorol; a- Calacorene; Decanal; trans-Cadina-1 (6), 4-diene; cis-para-Menth-2-en-l-ol; trans-para- Mentha-2,8-dien-l-ol; trans-Verbenol; Eugenol; Cyclosativene I; trans-Pinocarveol; Cryptone; Camphor; Longifolene; neo-Menthol; Isobomeol; Menthone; Citronellal; b- Copaene; 6-Methyl-5-hepten-2-one; cis-Rose oxide; (E)-6-Methyl-3,5-heptadien-2-one; g- Muurolene; a-Terpinyl acetate; a-Cubebene; 1-epi-Cubenol; Cyclosativene II; Santene; d- Elemene; allo-Aromadendrene; (E)^-Famesene; b-Santalene; a-Terpinene; Hanamyol; Serratol; Incensole; Tricyclene; Geranyl tiglate; (2E,6E)-Famesol; lO-epi-y-Eudesmol; Nerol; g-Amorphene; para-Cymenene; Terpinolene; trans-Linalool oxide (fur.); Isomenthone; a- Elemol; b-Elemene; (Z)-b-Ocimene; a-Phellandrene; (E)-a-Santalal; a-Selinene; Neryl acetate; a-Copaene; Caryophyllene oxide isomer; Caryophyllene oxide; Liguloxide analog II; b-Selinene; Thymol; Geranyl formate; g-Eudesmol; Methylchavicol; Terpinen-4-ol; a- Humulene; g-Terpinene; Methyl (E)-cinnamate; b-Bourbonene; Bomeol; Isoneral; a- Terpineol; Bomyl acetate; para-Cymene; Neral; Carvone; Methyleugenol; a-Gurjunene; 6,9- Guaiadiene; Citronellyl formate; trans-a-Bergamotene; a-Guaiene; Aromadendrene; Germacrene D; d-Cadinene; trans-Calamenene; Geranial; Camphene; a-Fenchene; a- Thujene; Geranyl acetate; b-Cubebene; b-Eudesmol; Neointermedeol; a-Eudesmol; Myrcene; 8-Hydroxy dihydroeremophilone; 8a-Hydroxyeremophila-l,l l-dien-9-one; (E)-b-Ocimene; Fokienol; Guaiol; Citronellol; A3-Carene; (Z)-y-Bisabolene; b-Bisabolene; b- Dihydroagarofuran; g-Cadinene; Elemicin; (E)-Nerolidol; Bulnesol; Hydroxyeremophilone; Eremophilone; a-Santalene; b-Caryophyllene; cis-a-Bergamotene; Sabinene; b-Pinene; Linalool; Nonanal; a-Pinene; Linalyl acetate; cis-Myrtanol; Geraniol; Limonene and/or 1,8- Cineole.

[00054] In one embodiment, the composition comprises at most 0.005% Ethanol; at most 0.005% 2-Methylpentane; at most 0.005% Isovaleral; at most 0.005% Isoamyl alcohol; at most 0.005% 3-Methylpentane; at most 0.005% 2-Methyl-3-buten-2-ol; 0.005% to 0.01% Toluene; 0.005% to 0.01% (3Z)-Hexenol; 0.005% to 0.01% Cyclohexane; 0.005% to 0.015% 5-Methylfurfural; 0.005% to 0.015% Hashishene; 0.005% to 0.015% meta-Cymene; 0.005% to 0.015% Camphenilone; 0.005% to 0.015% Styrene; 0.01% to 0.02% 3-

Methylcyclopentane; 0.01% to 0.02% Rosefuran; 0.02% to 0.05% Hexane; 0.02% to 0.05% trans-Carveol; 0.02% to 0.05% Sclareol; 0.02% to 0.05% trans-Rose oxide; 0.02% to 0.05% cis-para-Mentha-2,8-dien-l-ol; 0.02% to 0.05% Globulol; 0.02% to 0.05% cis-Sabinene hydrate; 0.02% to 0.05% Carvotanacetone; 0.02% to 0.05% Thuja-2,4(10)-diene; 0.02% to 0.05% Limona ketone; 0.02% to 0.05% Octanal; 0.02% to 0.05% cis-Linalool oxide (fur.); 0.02% to 0.05% Octyl acetate; 0.02% to 0.05% 4,5-diepi-Aristolochene; 0.02% to 0.05% Verbenone; 0.02% to 0.05% Neryl propionate; 0.02% to 0.05% Isogeranial; 0.02% to 0.05% a-Ylangene; 0.03% to 0.07% Viridiflorol; 0.03% to 0.07% a-Calacorene; 0.03% to 0.07% Decanal; 0.03% to 0.07% trans-Cadina- 1(6), 4-diene; 0.03% to 0.07% cis-para-Menth-2-en-l- ol; 0.03% to 0.07% trans-para-Mentha-2,8-dien-l-ol; 0.03% to 0.07% trans-Verbenol; 0.05% to 0.1% Eugenol; 0.05% to 0.1% Cyclosativene I; 0.05% to 0.1% trans-Pinocarveol; 0.05% to 0.1% Cryptone; 0.05% to 0.1% Camphor; 0.05% to 0.1% Longifolene; 0.05% to 0.1% neo- Menthol; 0.05% to 0.1% Isobomeol; 0.05% to 0.1% Menthone; 0.05% to 0.1% Citronellal; 0.07% to 0.15% b-Copaene; 0.07% to 0.15% 6-Methyl-5-hepten-2-one; 0.07% to 0.15% cis- Rose oxide; 0.07% to 0.15% (E)-6-Methyl-3,5-heptadien-2-one; 0.07% to 0.15% g- Muurolene; 0.07% to 0.15% a-Terpinyl acetate; 0.07% to 0.15% a-Cubebene; 0.07% to 0.15% 1-epi-Cubenol; 0.07% to 0.15% Cyclosativene II; 0.07% to 0.15% Santene; 0.07% to 0.15% d-Elemene; 0.07% to 0.15% allo-Aromadendrene; 0.07% to 0.15% (E)^-Famesene; 0.07% to 0.15% b-Santalene; 0.1% to 0.2% a-Terpinene; 0.1% to 0.2% Hanamyol; 0.1% to 0.2% Serratol; 0.1% to 0.2% Incensole; 0.1% to 0.2% Tricyclene; 0.1% to 0.2% Geranyl tiglate; 0.1% to 0.2% (2E,6E)-Famesol; 0.1% to 0.2% lO-epi-y-Eudesmol; 0.1% to 0.2% Nerol; 0.15% to 0.25% g-Amorphene; 0.2% to 0.5% para-Cymenene; 0.2% to 0.5% Terpinolene; 0.2% to 0.5% trans-Linalool oxide (fur.); 0.2% to 0.5% Isomenthone; 0.2% to 0.5% a-Elemol; 0.2% to 0.5% b-Elemene; 0.2% to 0.5% (Z)^-Ocimene; 0.2% to 0.5% a- Phellandrene; 0.2% to 0.5% (E)-a-Santalal; 0.2% to 0.5% a-Selinene; 0.2% to 0.5% Neryl acetate; 0.2% to 0.5% a-Copaene; 0.2% to 0.5% Caryophyllene oxide isomer; 0.2% to 0.5% Caryophyllene oxide; 0.2% to 0.5% Liguloxide analog II; 0.2% to 0.5% b-Selinene; 0.2% to 0.5% Thymol; 0.3% to 0.7% Geranyl formate; 0.3% to 0.7% g-Eudesmol; 0.3% to 0.7% Methylchavicol; 0.3% to 0.7% Terpinen-4-ol; 0.3% to 0.7% a-Humulene; 0.3% to 0.7% g- Terpinene; 0.3% to 0.7% Methyl (E)-cinnamate; 0.3% to 0.7% b-Bourbonene; 0.3% to 0.7% Bomeol; 0.3% to 0.7% Isoneral; 0.3% to 0.7% a-Terpineol; 0.3% to 0.7% Bomyl acetate; 0.3% to 0.7% para-Cymene; 0.3% to 0.7% Neral; 0.3% to 0.7% Carvone; 0.3% to 0.7% Methyleugenol; 0.3% to 0.7% a-Gurjunene; 0.5% to 1.0% 6,9-Guaiadiene; 0.5% to 1.0% Citronellyl formate; 0.5% to 1.0% trans-a-Bergamotene; 0.5% to 1.0% a-Guaiene; 0.5% to 1.0% Aromadendrene; 0.5% to 1.0% Germacrene D; 0.5% to 1.0% d-Cadinene; 0.5% to 1.0% trans-Calamenene; 0.5% to 1.0% Geranial; 0.7% to 1.5% Camphene; 0.7% to 1.5% a- Fenchene; 0.7% to 1.5% a-Thujene; 0.7% to 1.5% Geranyl acetate; 0.7% to 1.5% b- Cubebene; 0.7% to 1.5% b-Eudesmol; 0.7% to 1.5% Neointermedeol; 0.7% to 1.5% a- Eudesmol; 0.7% to 1.5% Myrcene; 0.7% to 1.5% 8-Hydroxydihydroeremophilone; 0.7% to 1.5% 8a-Hydroxyeremophila-l,ll-dien-9-one; 1.0% to 2.0% (E)^-Ocimene; 1.0% to 2.0% Fokienol; 1.0% to 2.0% Guaiol; 1.0% to 2.0% Citronellol; 1.0% to 2.0% A3-Carene; 1.5% to 2.5% (Z)-y-Bisabolene; 1.5% to 2.5% b-Bisabolene; 1.5% to 2.5% b-Dihydroagarofuran; 1.5% to 2.5% g-Cadinene; 1.5% to 2.5% Elemicin; 1.5% to 2.5% (E)-Nerobdol; 2.0% to 5.0% Bulnesol; 2.0% to 5.0% Hydroxyeremophilone; 2.0% to 5.0% Eremophilone; 2.0% to 5.0% a-Santalene; 2.0% to 5.0% b-Caryophyllene; 2.0% to 5.0% cis-a-Bergamotene; 3.0% to 7.0% Sabinene; 3.0% to 7.0% b-Pinene; 3.0% to 7.0% Linalool; 3.0% to 7.0% Nonanal; 3.0% to 7.0% a-Pinene; 9.0% to 12% Linalyl acetate; 9.0% to 12% cis-Myrtanol; 9.0% to 12% Geraniol; 10% to 14% Limonene and/or 10% to 14% 1,8-Cineole.

[00055] In another embodiment, the composition comprises Citrus aurantiifolia,

Leptospermum scoparium, Copaifera officinalis, Citrus limon, Citrus sinensis, Vanilla planifolia, Pimento officinalis, Carum carvi, Cinnamomum zeylanicum, Cananga odorata var. Genuina, Jasminum grandiflorum I... Lavandula angustifolia and/or ogos lemon cablin. [00056] In one embodiment, the composition comprises 4.0% to 7.0% Citrus aurantiifolia, 2.0% to 4.0% Leptospermum scoparium, 2.0% to 4.0% Copaifera officinalis, 1.5% to 2.5% Citrus limon, 1.5% to 2.5% Citrus sinensis, 1.0% to 2.0% Vanilla planifolia, 0.1% to 1.0% Pimento officinalis, 0.1% to 1.0% Carum carvi, 0.1% to 1.0% Cinnamomum zeylanicum, 0.1% to 1.0% Cananga odorata var. Genuina, 0.1% to 0.7% Jasminum grandiflorum I... 0.1% to 0.7% Lavandula angustifolia and/or 0.1% to 0.7% Pogostemon cablin.

[00057] In another embodiment, the composition comprises Isovaleral; 2,4-Dimethyl- 3-pentanone; Hexanol; 2-Methyl-3-buten-2-ol; 4,5-Dihydrotoluene; Octane; Ethanol; Thuja- 2, 4(10)-diene; allo-Ocimene; Isovaleric acid; 3-Methyl-3-butenyl acetate; Tricyclene; Octen- 3-one; Isobomeol; trans-Carvone oxide; Methyl kolavenate; 6-Methyl-5-hepten-2-one; cis- Carvone oxide; Benzaldehyde; cis-Linalool oxide (fur.); Octanol; a-Ylangene; Camphor; cis- Sabinene hydrate; Toluene; Nonane; Heptanal; Bomylene; (Z,Z)-Geranyl linalool; Citropten; Nonanal; Octen-3-yl acetate; A3-Carene: Perillaldehyde; Methyl linoleate; (E)-Anethole; Elemicin; Citronellal; cis-Limonene oxide; b-Bourbonene; Juniper camphor; Amyl isovalerate; 6,9-Guaiadiene; Manool; trans-Dihydrocarvone; trans-Isopiperitenol; Decanal; Isocaryophyllene epoxide B; Viridiflorol; cis-Dihydrocarvone; para-Cresol; Isoterpinolene; Octan-3-one; trans-Carveol; Humulene epoxide II; (3Z)-Caryophylla-3,8(13)-dien-5 -ol; Linoleic acid; b-Cubebene; Lavandulyl acetate; Indole; Ethyl benzoate; Phytol; para-Cymen- 8-ol; Isophytol; Kolavelool; b-Patchoulene; a-Thujene; Prenyl acetate; Methyl benzoate; g- Patchoulene; Globulol; Oleic acid; (2E,6E)-Famesol; 1-Terpineol; trans-Limonene oxide; g- Terpineol; Stearic acid; (E)-Cinnamal; (E)-Jasmone; d-Elemene; Safrole; Kolavenol; Neointermedeol; endo-Fenchol; a-Calacorene; (Z)-b-Ocimene; b-Copaene; 9-erί-b- Caryophyllene; (E)-b-Famesene; cis^-Terpineol: Epoxyterpinolene; Caryophyllenyl alcohol; b-Calacorene; Citronellol; cis-Carveol; Grandiflorone; Ethyl linoleate; Palmitic acid; Junenol; Benzyl salicylate; (E)-b-Ocimene; Spathulenol; allo-Aromadendrene; Germacrene B; Terpinen-4-ol; (2E,6E)-Famesyl acetate; Eugenyl acetate; g-Amorphene; Pseudolimonene; Octanal; a-Phellandrene; Neryl acetate; Benzyl acetate; Bomeol; Geranyl acetate; Camphene; a-Fenchene; a-Muurolene; Geranial; x-Cadinol; x-Muurolol; g-Muurolene; b-Elemene; Caryophyllene oxide; Caryophyllene oxide isomer; trans-Cadina-1 (6), 4-diene; d-Guaiene; Methyleugenol; a-Gurjunene; a-Patchoulene; a-Cubebene; trans-Cadina-1, 4-diene; Benzyl benzoate; Linalyl acetate; Geraniol; b-Selinene; a-Pinene; Myrcene; a-Selinene; Bicyclogermacrene; Isoleptospermone; Flavesone; Patchoulol; a-Cadinol; Pogostol; a- Humulene; (E)-Isoeugenol; Linalool; a-Terpineol; a-Terpinene; 1,4-Cineole; a-Copaene; a- Guaiene; Aromadendrene; trans-a-Bergamotene; Seychellene; Germacrene D; g-Cadinene; b- Bisabolene; (3E,6E)-a-Famesene; Sabinene; b-Pinene; Geranic oxide; Terpinolene; Leptospermone; Carvone; Neral; trans-Calamenene; d-Cadinene; g-Terpinene; Eugenol; b- Caryophyllene; cis-a-Bergamotene; para-Cymene; Limonene and/or 1,8-Cineole. [00058] In one embodiment, the composition comprises at most 0.005% Isovaleral; at most 0.005% 2,4-Dimethyl-3-pentanone; at most 0.005% Hexanol; at most 0.005% 2- Methyl-3-buten-2-ol; at most 0.005% 4,5-Dihydrotoluene; at most 0.005% Octane; at most 0.005% Ethanol; at most 0.005% Thuja-2, 4(10)-diene; 0.005% to 0.01% allo-Ocimene; 0.005% to 0.01% Isovaleric acid; 0.005% to 0.01% 3-Methyl-3-butenyl acetate; 0.005% to 0.01% Tricyclene; 0.005% to 0.01% Octen-3-one; 0.005% to 0.01% Isobomeol; 0.005% to 0.015% trans-Carvone oxide; 0.005% to 0.015% Methyl kolavenate; 0.005% to 0.015% 6- Methyl-5-hepten-2-one; 0.005% to 0.015% cis-Carvone oxide; 0.005% to 0.015% Benzaldehyde; 0.005% to 0.015% cis-Linalool oxide (fur.); 0.005% to 0.015% Octanol; 0.005% to 0.015% a-Ylangene; 0.01% to 0.02% Camphor; 0.01% to 0.02% cis-Sabinene hydrate; 0.01% to 0.02% Toluene; 0.01% to 0.02% Nonane; 0.01% to 0.02% Heptanal; 0.01% to 0.02% Bomylene; 0.01% to 0.02% (Z,Z)-Geranyl linalool; 0.01% to 0.02% Citropten; 0.015% to 0.025% Nonanal; 0.015% to 0.025% Octen-3-yl acetate; 0.015% to 0.025% A3-Carene; 0.015% to 0.025% Perillaldehyde; 0.015% to 0.025% Methyl linoleate; 0.015% to 0.025% (E)-Anethole; 0.015% to 0.025% Elemicin; 0.02% to 0.05% Citronellal; 0.02% to 0.05% cis-Limonene oxide; 0.02% to 0.05% b-Bourbonene; 0.02% to 0.05% Juniper camphor; 0.02% to 0.05% Amyl isovalerate; 0.02% to 0.05% 6,9-Guaiadiene; 0.02% to 0.05% Manool; 0.02% to 0.05% trans-Dihydrocarvone; 0.02% to 0.05% trans- Isopiperitenol; 0.02% to 0.05% Decanal; 0.02% to 0.05% Isocaryophyllene epoxide B; 0.02% to 0.05% Viridiflorol; 0.02% to 0.05% cis-Dihydrocarvone; 0.02% to 0.05% para-Cresol; 0.02% to 0.05% Isoterpinolene; 0.02% to 0.05% Octan-3-one; 0.02% to 0.05% trans-Carveol; 0.02% to 0.05% Humulene epoxide II; 0.02% to 0.05% (3Z)-Caryophylla-3,8(13)-dien-5 -ol; 0.02% to 0.05% Linoleic acid; 0.03% to 0.07% b-Cubebene; 0.03% to 0.07% Lavandulyl acetate; 0.03% to 0.07% Indole; 0.03% to 0.07% Ethyl benzoate; 0.03% to 0.07% Phytol; para-Cymen-8-ol; 0.03% to 0.07% Isophytol; 0.05% to 0.1% Kolavelool; 0.05% to 0.1% b- Patchoulene; 0.05% to 0.1% a-Thujene; 0.05% to 0.1% Prenyl acetate; 0.05% to 0.1% Methyl benzoate; 0.05% to 0.1% g-Patchoulene; 0.05% to 0.1% Globulol; 0.05% to 0.1% Oleic acid; 0.05% to 0.1% (2E,6E)-Famesol; 0.05% to 0.1% 1-Terpineol; 0.05% to 0.1% trans-Limonene oxide; 0.05% to 0.1% g-Terpineol; 0.05% to 0.1% Stearic acid; 0.05% to 0.1% (E)-Cinnamal; 0.05% to 0.1% (E)-Jasmone; 0.05% to 0.1% d-Elemene; 0.07% to 0.15% Safrole; 0.07% to 0.15% Kolavenol; 0.07% to 0.15% Neointermedeol; 0.07% to 0.15% endo- Fenchol; 0.07% to 0.15% a-Calacorene; 0.07% to 0.15% (Z)^-Ocimene; 0.07% to 0.15% b- Copaene; 0.07% to 0.15% 9-epi^-Caryophyllene; 0.07% to 0.15% (E)^-Famesene; 0.07% to 0.15% cis^-Terpineol; 0.07% to 0.15% Epoxyterpinolene; 0.07% to 0.15% Caryophyllenyl alcohol; 0.07% to 0.15% b-Calacorene; 0.07% to 0.15% Citronellol; 0.07% to 0.15% cis-Carveol; 0.1% to 0.2% Grandiflorone; 0.1% to 0.2% Ethyl linoleate; 0.1% to 0.2% Palmitic acid; 0.1% to 0.2% Junenol; 0.1% to 0.2% Benzyl salicylate; 0.1% to 0.2% (E)- -Ocimene; 0.1% to 0.2% Spathulenol; 0.1% to 0.2% allo-Aromadendrene; 0.1% to 0.2% Germacrene B; 0.1% to 0.2% Terpinen-4-ol; 0.15% to 0.25% (2E,6E)-Famesyl acetate; 0.15% to 0.25% Eugenyl acetate; 0.15% to 0.25% g-Amorphene; 0.15% to 0.25% Pseudolimonene; 0.15% to 0.25% Octanal; 0.15% to 0.25% a-Phellandrene; 0.15% to 0.25% Neryl acetate; 0.2% to 0.5% Benzyl acetate; 0.2% to 0.5% Bomeol; 0.2% to 0.5% Geranyl acetate; 0.2% to 0.5% Camphene; 0.2% to 0.5% a-Fenchene; 0.2% to 0.5% a-Muurolene; 0.2% to 0.5% Geranial; 0.2% to 0.5% x-Cadinol; 0.2% to 0.5% x-Muurolol; 0.2% to 0.5% g- Muurolene; 0.2% to 0.5% b-Elemene; 0.2% to 0.5% Caryophyllene oxide; 0.2% to 0.5% Caryophyllene oxide isomer; 0.2% to 0.5% trans-Cadina-1 (6), 4-diene; 0.3% to 0.7% d- Guaiene; 0.3% to 0.7% Methyleugenol; 0.3% to 0.7% a-Gurjunene; 0.3% to 0.7% a- Patchoulene; 0.3% to 0.7% a-Cubebene; 0.3% to 0.7% trans-Cadina-1, 4-diene; 0.3% to 0.7% Benzyl benzoate; 0.5% to 1.0% Linalyl acetate; 0.5% to 1.0% Geraniol; 0.5% to 1.0% b- Sebnene; 0.5% to 1.0% a-Pinene; 0.5% to 1.0% Myrcene; 0.5% to 1.0% a-Sebnene; 0.5% to 1.0% Bicyclogermacrene; 0.5% to 1.0% Isoleptospermone; 0.5% to 1.0% Flavesone; 0.7% to 1.5% Patchoulol; 0.7% to 1.5% a-Cadinol; 0.7% to 1.5% Pogostol; 0.7% to 1.5% a- Humulene; 0.7% to 1.5% (E)-Isoeugenol; 0.7% to 1.5% Linalool; 0.7% to 1.5% a-Terpineol; 0.7% to 1.5% a-Terpinene; 0.7% to 1.5% 1,4-Cineole; 0.7% to 1.5% a-Copaene; 1.0% to 2.0% a-Guaiene; 1.0% to 2.0% Aromadendrene; 1.0% to 2.0% trans-a-Bergamotene; 1.0% to 2.0% Seychellene; 1.0% to 2.0% Germacrene D; 1.0% to 2.0% g-Cadinene; 1.0% to 2.0% b- Bisabolene; 1.0% to 2.0% (3E,6E)-a-Famesene; 1.5% to 2.5% Sabinene; 1.5% to 2.5% b- Pinene; 1.5% to 2.5% Geranic oxide; 2.0% to 5.0% Terpinolene; 2.0% to 5.0% Leptospermone; 2.0% to 5.0% Carvone; 2.0% to 5.0% Neral; 2.0% to 5.0% trans- Calamenene; 2.0% to 5.0% d-Cadinene; 2.0% to 5.0% g-Terpinene; 3.0% to 7.0% Eugenol; 5.0% to 8.0% b-Caryophyllene; 5.0% to 8.0% cis-a-Bergamotene; 32% to 36% para- Cymene; 32% to 36% Limonene and/or 32% to 36% 1,8-Cineole.

[00059] In another embodiment, the composition comprises Cupressus sempervirens I... Pinus sylvestris I... Canarium luzonicum(Blume) A.Gray, Boswellia carterii, Citrus aurantiifolia, Citrus sinensis (L.) Osbeck, Piper nigrum, Rosmarinus officinalis (L.) ct cineole, Juniperus virginiana, Pseudotsuga menziesii(Mirb.) Franco, Santalum Spicatum, Citrus aurantium var. bergamia, Juniperus communis L, Citrus reticulata Blanco, Pelargonium graveolens var roseum, Copaifera officinalis, Abies balsamea (L.) Mill., Zingiber officinale Roscoe, Mentha x piperita L., Mentha spicata L., Picea mariana (Mill.) Britton et al, Litsea cubeba, Pimento officinalis, Leptospermum scoparium, Cyperus scariosus R.Br., Curcuma longa L. and/or Ferula galbaniflua Boiss. & Buhse.

[00060] In one embodiment, the composition comprises 1.5% to 2.5% Cupressus sempervirens L., 1.0% to 2.0% Pinus sylvestris L., 1.0% to 2.0% Canarium luzonicum(Blume) A.Gray, 0.5% to 1.5% Boswellia carterii, 0.5% to 1.5% Citrus aurantiifolia, 0.5% to 1.5% Citrus sinensis (L.) Osbeck, 0.5% to 1.5% Piper nigrum, 0.5% to 1.5% Rosmarinus officinalis (L.) ct cineole, 0.5% to 1.5% Juniperus virginiana, 0.5% to 1.5% Pseudotsuga menziesii(Mirb.) Franco, 0.5% to 1.5% Santalum Spicatum, 0.5% to 1.5% Citrus aurantium var. bergamia, 0.5% to 1.5% Juniperus communis L, 0.1% to 1.0% Citrus reticulata Blanco, 0.1% to 1.0% Pelargonium graveolens var roseum, 0.1% to 1.0% Copaifera officinalis, 0.1% to 1.0% Abies balsamea (L.) Mill., 0.1% to 1.0% Zingiber officinale Roscoe, 0.1% to 1.0% Mentha x piperita L. , 0.1% to 1.0 % Mentha spicata L., 0.1% to 1.0% Picea mariana (Mill.) Britton et al, 0.1% to 1.0% Litsea cubeba, 0.1% to 1.0% Pimento officinalis, 0.1% to 1.0% Leptospermum scoparium, 0.1% to 1.0% Cyperus scariosus R.Br., 0.1% to 1.0% Curcuma longa L. and/or 0.05% to 0.15% Ferula galbaniflua Boiss. & Buhse.

[00061] In another embodiment, the composition comprises 2-Methylbutyral; Isoamyl alcohol; Ethyl 2-methylbutyrate; 2-Methyl-3-buten-2-ol; Isovaleral; 2-Heptanone; trans-2,5- Diethyltetrahydrofuran; 2-Ethylfuran; Ethanol; Bomylene; Benzaldehyde; Octan-3-ol; Octen- 3-yl acetate; Hexanal; Citropten; Toluene; (2E)-Hexenal; 2-Heptanol; Octanol; Hexanol; cis- Linalool oxide (fur.); Manool; Cembrenol; (3Z)-Hexenol; trans-Dihydrocarvone; a- Longipinene; Bergapten; Hashishene; Octen-3-ol; meta-Cymene; trans-Rose oxide; Grandiflorone; Octan-3-yl acetate; Dihydroedulan I; Dihydrocarvyl acetate; Kolavelool; Kolavenol; cis-Limonene oxide; Citronellal; neo-Menthyl acetate; Octyl acetate; Cyclosativene I; Thuja-2,4(10)-diene; Nonanal; Isoterpinolene; endo-Fenchyl acetate; trans- Sabinene hydrate; (E)-a-Santalol; trans-Carveol; (E)-a-Atlantone; (E)-a-trans-Bergamotol; Viridiflorol; meta-Camphorene; Carvotanacetone; trans-para-Mentha-2,8-dien-l-ol; a- Guaiene; Isomenthol; (E)-a-Santalal; 10-epi- -Acoradiene; Isospathulenol; Isogeranial; Decanal; Globulol; Isoneral; Dihydrocarveol; neo-Menthol; Verbenone; Cyclosativene II; a- Ylangene; a-Himachalene; a-Cadinol; (E)-Nerolidol; Spathulenol; (Z)- -Ocimene; para- Cymen-8-ol; Piperitone; (E)- -Santalol; a-Calacorene; a-Santalene; Germacrene B; cis-Rose oxide; b-Thujone; endo-Fenchol; Isobomeol; Karahanaenone; allo-Aromadendrene; cis- Sabinene hydrate; cis-para-Mentha-2,8-dien-l-ol; trans-Limonene oxide; trans-Pinocarveol; b-Eudesmol; cis-Carveol; Thymol methyl ether analog I; Camphene hydrate; a-Chamigrene; neoiso-Menthol; cis-Dihydrocarvone; Flavesone; (Z)^-Curcumen-l 2-ol: Isoleptospermone; neo-Dihydrocarveol; Rotundene; d-Elemene; Neryl acetate; Serratol; Incensole; a- Muurolene; Santene; lO-epi-y-Eudesmol; Cubenol; x-Cadinol; x-Muurolol; Menthyl acetate; Octan-3-one; 6-Methyl-5-hepten-2-one; Geranyl formate; Tricyclene; 6,9-Guaiadiene; trans- Cadina- 1,4-diene; b-Santalene; (E)-b-Famesene; b-Cubebene; Geranyl acetate; g-Muurolene; epi-b-Santalene; trans-Cadina- 1(6), 4-diene; Elemicin; (E)-b-Ocimene; l,5-diepi^- Bourbonene; b-Bourbonene; b-Elemene; Cyperotundone; (Z)-Nuciferol; Aromadendrene; b- Sesquiphellandrene; (Z)-epi-b-Santalol; Citronellyl formate; Isomenthone; Menthofuran; b- Turmerone; (E)-y-Atlantone; Caryophyllene oxide; Caryophyllene oxide isomer; (Z)-a-trans- Bergamotol; (Z)-y-Atlantone; Cyperene; (Z)-Jasmone; Leptospermone; 1,4-Cineole; a- Terpinene; Bomeol; a-Turmerone; Germacrene D; ar-Turmerone; a-Elemol; Bicyclogermacrene; Viridiflorene; a-Selinene; ar-Curcumene; b-Selinene; a-Humulene; 2- epi-a-Funebrene; a-Copaene; (Z)-Lanceol; a-Terpinyl acetate; a-Cubebene; Menthone; Camphor; a-Zingiberene; b-Himachalene; a-Phellandrene; Pseudolimonene; Octanal; g- Cadinene; 7-epi-a-Selinene; (3E,6E)-a-Famesene; a-Thujene; a-Terpineol; a-Thujone; Linalool; Geranial; d-Cadinene; trans-Calamenene; Zonarene; a-Cedrol; (Z)-b-Santalol; (Z)- a-Atlantone; Pulegone; Citronellol; Eugenol; Bomyl acetate; 3-Methylcyclohexanone; Camphene; a-Fenchene; Geraniol; Linalyl acetate; Myrcene; para-Cymenene; Terpinolene; trans-Linalool oxide (fur.); Terpinen-4-ol; Menthol; cis-Thujopsene; b-Copaene; Carvone; Neral; (Z)-a-Santalol; g-Terpinene; a-Cedrene; Methyleugenol; Dimethyl anthranilate; D3- Carene; b-Caryophyllene; b-Cedrene; b-Pinene; Sabinene; a-Pinene; para-Cymene; Limonene and/or 1,8-Cineole.

[00062] In one embodiment, the composition comprises at most 0.005% 2- Methylbutyral; at most 0.005% Isoamyl alcohol; at most 0.005% Ethyl 2-methylbutyrate; at most 0.005% 2-Methyl-3-buten-2-ol; Isovaleral; at most 0.005% 2-Heptanone; at most 0.005% trans-2,5-Diethyltetrahydrofuran; at most 0.005% 2-Ethylfuran; at most 0.005% Ethanol; at most 0.005% Bomylene; at most 0.005% Benzaldehyde; at most 0.005% Octan-3- ol; at most 0.005% Octen-3-yl acetate; at most 0.005% Hexanal; 0.005% to 0.01% Citropten; 0.005% to 0.01% Toluene; 0.005% to 0.01% (2E)-Hexenal; 0.005% to 0.01% 2-Heptanol; 0.005% to 0.015% Octanol; 0.005% to 0.015% Hexanol; 0.005% to 0.015% cis-Linalool oxide (fur.); 0.005% to 0.015% Manool; 0.005% to 0.015% Cembrenol; 0.005% to 0.015% (3Z)-Hexenol; 0.005% to 0.015% trans-Dihydrocarvone; 0.005% to 0.015% a-Longipinene; 0.005% to 0.015% Bergapten; 0.01% to 0.02% Hashishene; 0.01% to 0.02% Octen-3-ol; 0.01% to 0.02% meta-Cymene; 0.01% to 0.02% trans-Rose oxide; 0.01% to 0.02% Grandiflorone; 0.01% to 0.02% Octan-3-yl acetate; 0.01% to 0.02% Dihydroedulan I; 0.01% to 0.02% Dihydrocarvyl acetate; 0.01% to 0.02% Kolavelool; 0.01% to 0.02% Kolavenol; 0.01% to 0.02% cis-Limonene oxide; 0.01% to 0.02% Citronellal; 0.01% to 0.02% neo- Menthyl acetate; 0.015% to 0.025% Octyl acetate; 0.015% to 0.025% Cyclosativene I; 0.015% to 0.025% Thuja-2, 4(10)-diene; 0.015% to 0.025% Nonanal; 0.015% to 0.025% Isoterpinolene; 0.015% to 0.025% endo-Fenchyl acetate; 0.015% to 0.025% trans-Sabinene hydrate; 0.015% to 0.025% (E)-a-Santalol; 0.02% to 0.05% trans-Carveol; 0.02% to 0.05% (E)-a-Atlantone; 0.02% to 0.05% (E)-a-trans-Bergamotol; 0.02% to 0.05% Viridiflorol; 0.02% to 0.05% meta-Camphorene; 0.02% to 0.05% Carvotanacetone; 0.02% to 0.05% trans- para-Mentha-2,8-dien-l-ol; 0.02% to 0.05% a-Guaiene; 0.02% to 0.05% Isomenthol; 0.02% to 0.05% (E)-a-Santalal; 0.02% to 0.05% 10-epi^-Acoradiene; 0.02% to 0.05% Isospathulenol; 0.02% to 0.05% Isogeranial; 0.02% to 0.05% Decanal; 0.02% to 0.05% Globulol; 0.02% to 0.05% Isoneral; 0.02% to 0.05% Dihydrocarveol; 0.02% to 0.05% neo- Menthol; 0.02% to 0.05% Verbenone; 0.03% to 0.07% Cyclosativene II; 0.03% to 0.07% a- Ylangene; 0.03% to 0.07% a-Himachalene; 0.03% to 0.07% a-Cadinol; 0.03% to 0.07% (E)- Nerolidol; 0.03% to 0.07% Spathulenol; 0.03% to 0.07% (Z)^-Ocimene; 0.03% to 0.07% para-Cymen-8-ol; 0.03% to 0.07% Piperitone; 0.03% to 0.07% (E)^-Santalol; 0.03% to 0.07% a-Calacorene; 0.03% to 0.07% a-Santalene; 0.03% to 0.07% Germacrene B; 0.05% to 0.1% cis-Rose oxide; 0.05% to 0.1% b-Thujone; 0.05% to 0.1% endo-Fenchol; 0.05% to 0.1% Isobomeol; 0.05% to 0.1% Karahanaenone; 0.05% to 0.1% allo-Aromadendrene; 0.05% to 0.1% cis-Sabinene hydrate; 0.05% to 0.1% cis-para-Mentha-2,8-dien-l-ol; 0.05% to 0.1% trans-Limonene oxide; 0.05% to 0.1% trans-Pinocarveol; 0.05% to 0.1% b-Eudesmol; 0.05% to 0.1% cis-Carveol; 0.05% to 0.1% Thymol methyl ether analog I; 0.05% to 0.1% Camphene hydrate; 0.07% to 0.15% a-Chamigrene; 0.07% to 0.15% neoiso-Menthol; 0.07% to 0.15% cis-Dihydrocarvone; 0.07% to 0.15% Flavesone; 0.07% to 0.15% (Z)^-Curcumen- 12-ol; 0.07% to 0.15% Isoleptospermone; 0.07% to 0.15% neo-Dihydrocarveol; 0.07% to 0.15% Rotundene; 0.07% to 0.15% d-Elemene; 0.07% to 0.15% Neryl acetate; 0.07% to 0.15% Serratol; 0.07% to 0.15% Incensole; 0.07% to 0.15% a-Muurolene; 0.07% to 0.15% Santene; 0.07% to 0.15% lO-epi-y-Eudesmol; 0.07% to 0.15% Cubenol; 0.07% to 0.15% x- Cadinol; 0.07% to 0.15% x-Muurolol; 0.1% to 0.2% Menthyl acetate; 0.1% to 0.2% Octan-3- one; 0.1% to 0.2% 6-Methyl-5-hepten-2-one; 0.1% to 0.2% Geranyl formate; 0.1% to 0.2% Tricyclene; 0.1% to 0.2% 6,9-Guaiadiene; 0.1% to 0.2% trans-Cadina-1, 4-diene; 0.1% to 0.2% b-Santalene; 0.1% to 0.2% (E)^-Famesene; 0.1% to 0.2% b-Cubebene; 0.1% to 0.2% Geranyl acetate; 0.1% to 0.2% g-Muurolene; 0.1% to 0.2% epi^-Santalene; 0.1% to 0.2% trans-Cadina- 1(6), 4-diene; 0.1% to 0.2% Elemicin; 0.1% to 0.2% (E)^-Ocimene; 0.1% to 0.2% l,5-diepi^-Bourbonene; 0.1% to 0.2% b-Bourbonene; 0.1% to 0.2% b-Elemene; 0.15% to 0.25% Cyperotundone; 0.15% to 0.25% (Z)-Nuciferol; 0.15% to 0.25% Aromadendrene; 0.15% to 0.25% b-Sesquiphellandrene; 0.2% to 0.5% (Z)-epi^-Santalol; 0.2% to 0.5% Citronellyl formate; 0.2% to 0.5% Isomenthone; 0.2% to 0.5% Menthofuran; 0.2% to 0.5% b- Turmerone; 0.2% to 0.5% (E)-y-Atlantone; 0.2% to 0.5% Caryophyllene oxide; 0.2% to 0.5% Caryophyllene oxide isomer; 0.2% to 0.5% (Z)-a-trans-Bergamotol; 0.2% to 0.5% (Z)-g- Atlantone; 0.2% to 0.5% Cyperene; 0.2% to 0.5% (Z)-Jasmone; 0.2% to 0.5% Leptospermone; 0.2% to 0.5% 1,4-Cineole; 0.2% to 0.5% a-Terpinene; 0.2% to 0.5% Bomeol; 0.3% to 0.7% a-Turmerone; 0.3% to 0.7% Germacrene D; 0.3% to 0.7% ar-

Turmerone; 0.3% to 0.7% a-Elemol; 0.3% to 0.7% Bicyclogermacrene; 0.3% to 0.7%

Viridiflorene; 0.3% to 0.7% a-Selinene; 0.3% to 0.7% ar-Curcumene; 0.3% to 0.7% b- Selinene; 0.3% to 0.7% a-Humulene; 0.3% to 0.7% 2-epi-a-Funebrene; 0.3% to 0.7% a-

Copaene; 0.3% to 0.7% (Z)-Lanceol; 0.3% to 0.7% a-Terpinyl acetate; 0.3% to 0.7% a-

Cubebene; 0.3% to 0.7% Menthone; 0.3% to 0.7% Camphor; 0.5% to 1.0% a-Zingiberene; 0.5% to 1.0% b-Himachalene; 0.5% to 1.0% a-Phellandrene; 0.5% to 1.0% Pseudolimonene; 0.5% to 1.0% Octanal; 0.5% to 1.0% g-Cadinene; 0.5% to 1.0% 7-epi-a-Selinene; 0.5% to 1.0% (3E,6E)-a-Famesene; 0.5% to 1.0% a-Thujene; 0.5% to 1.0% a-Terpineol; 0.5% to 1.0% a-Thujone; 0.5% to 1.0% Linalool; 0.5% to 1.0% Geranial; 0.5% to 1.0% d-Cadinene; 0.5% to 1.0% trans-Calamenene; 0.5% to 1.0% Zonarene; 0.7% to 1.5% a-Cedrol; 0.7% to 1.5% (Z)^-Santalol; 0.7% to 1.5% (Z)-a-Atlantone; 0.7% to 1.5% Pulegone; 0.7% to 1.5% Citronellol; 0.7% to 1.5% Eugenol; 0.7% to 1.5% Bomyl acetate; 1.0% to 2.0% 3- Methylcyclohexanone; 1.0% to 2.0% Camphene; 1.0% to 2.0% a-Fenchene; 1.0% to 2.0% Geraniol; 1.0% to 2.0% Linalyl acetate; 1.0% to 2.0% Myrcene; 1.0% to 2.0% para- Cymenene; 1.0% to 2.0% Terpinolene; 1.0% to 2.0% trans-Linalool oxide (fur.); 1.0% to 2.0% Terpinen-4-ol; 1.0% to 2.0% Menthol; 1.5% to 2.5% cis-Thujopsene; 1.5% to 2.5% b- Copaene; 1.5% to 2.5% Carvone; 1.5% to 2.5% Neral; 1.5% to 2.5% (Z)-a-Santalol; 1.5% to 2.5% g-Terpinene; 3.0% to 5.0% a-Cedrene; 3.0% to 5.0% Methyleugenol; 3.0% to 5.0% Dimethyl anthranilate; 3.0% to 5.0% A3-Carene; 3.0% to 5.0% b-Caryophyllene; 3.0% to 5.0% b-Cedrene; 5.0% to 8.0% b-Pinene; 5.0% to 8.0% Sabinene; 12% to 15% a-Pinene; 20% to 24% para-Cymene; 20% to 24% Limonene and/or 20% to 24% 1,8-Cineole.

[00063] In another embodiment, the composition comprises Citrus aurantium var. bergamia, Cedrus deodara (Roxb. ex D. Don) G.Don, Cupressus sempervirens I... Eucalyptus globulus Labill, Pseudotsuga menziesii(Mirb.) Franco, Boswellia frereana Birdw., Pelargonium graveolensL’Hir. , Juniperus communis L, Lavandula angustifolia, Citrus limon, Cymbopogon citratus, Citrus aurantiifolia, Litsea cubeba, Leptospermum scoparium, Citrus aurantium var.amara L., Mentha x piperita L., Pinus sylvestris L., Citrus reticulata Blanco and/or Cananga odorata var. Genuina.

[00064] In one embodiment, the composition comprises 1.5% to3.5% Citrus aurantium var. bergamia, 0.5% to 1.5% Cedrus deodara (Roxb. ex D. Don) G.Don, 0.1% to 0.5% Cupressus sempervirens L., 0.5% to 1.5% Eucalyptus globulus Labill, 0.1% to 0.5% Pseudotsuga menziesii(Mirb.) Franco, 0.1% to 1.0% Boswellia frereana Birdw., 0.5% to 1.5% Pelargonium graveolensL'H r. , 0.1% to 0.5% Juniperus communis L, 0.5% to 1.5% Lavandula angustifolia, 1.5% to 2.5% Citrus limon, 1.0% to 2.0% Cymbopogon citratus, 3.0% to 5.0% Citrus aurantiifolia, 2.0% to 4.0% Litsea cubeba, 0.2% to 0.4% Leptospermum scoparium, 0.3% to 0.5% Citrus aurantium var.amara L., 0.8% to 1.0 % Mentha x piperita L., 0.1% to 0.3% Pinus sylvestris L., 2.0% to 4.0% Citrus reticulata Blanco and/or 0.5% to 1.5% Cananga odorata var. Genuina.

[00065] In another embodiment, the composition comprises 2-Methylbutyral; 2-

Methylbutanol; Prenol; 4-Heptanone; Ethanol; Isovaleral; Isoamyl alcohol; (2E)-Hexenal; trans-Rose oxide; 2-Ethylfuran; Hexanal; (3Z)-Hexenol; Geranyl benzoate; 2-Methyl-3- buten-2-ol; Benzaldehyde; a-Bisabolol; Oxypeucedanin; 6-Methyl-5-hepten-2-ol; Viridiflorol; 3-Methyl-3-butenyl acetate; a-Gurjunene; (2E,6E)-Famesal; Geranyl heptanoate; Hexanol; Hashishene; 4-Nonanol; Geranyl valerate; Nootkatone; para- Camphorene; Toluene; Nonane; neoiso-Menthol; Thuja-2,4(10)-diene; Octanol; d-Elemene; b-Himachalene oxide; Nonanal; a-Elemol; a-Sinensal; Octen-3-ol; (Z)-a-Bisabolene; Longibomeol; (2E,6Z)-Famesol; Grandiflorone; Stearic acid; Isomenthyl acetate; trans- Isopiperitenol; meta-Camphorene; Piperitenone; Cyclosativene I; Tricyclene; Himachalene epoxide; Citropten; Bergapten; trans-Carveol; Cyclosativene II; Germacrene B; Linoleic acid; trans-Sabinene hydrate; Verbenone; Oleic acid; Spathulenol; trans-Chrysanthemal; Deodarone epimer I; Dodecanal; cis-Linalool oxide (fur.); Isomenthol; cis-Limonene oxide; trans-para-Mentha-2,8-dien-l-ol; Octen-3-yl acetate; Himachala-2, 4-diene; a-Agarofuran; Flavesone; cis-Sabinene hydrate; cis-para-Menth-2-en-l-ol; g-Terpineol; Octanal; Camphor; Geranyl butyrate; Humulene epoxide II; 4-Nonanone; b-Copaene; Phenylethyl tiglate; Allohimachalol; ar-Himachalene; a-Cadinene; Lavandulol; Ethyl benzoate; Octyl acetate; a- Santalene; Piperitone; Palmitic acid; trans-Cadina- 1(6), 4-diene; Methyl benzoate; Limona ketone; Octan-3-yl acetate; Decanal; para-Cymen-8-ol; Longifolene; Caryophyllenyl alcohol; Prenyl benzoate; Isoleptospermone; (E)-Isoeugenol; (E)-Vestitenone; Citronellyl propionate; b-Elemene; a-Cadinol; Citronellyl acetate; Eugenol; b-Atlantone; (E)-10,ll- Dihydroatlantone; (2E,6E)-Famesol; Bomyl acetate; x-Muurolol; Cubenol; x-Cadinol; (Z)-a- Atlantone; b-Selinene; l,5-diepi-b-Bourbonene; b-Bourbonene; Citronellal; exo-Isocitral; Epoxyterpinolene; Isogeranial; 1-Terpineol; trans-Limonene oxide; lO-epi-y-Eudesmol; 6,9- Guaiadiene; Himachal ol; Citronellyl butyrate; cis-Rose oxide; endo-Fenchol; b-Thujone; b- Santalene; (E)-b-Famesene; (Z)-y-Atlantone; Nerol; (E)-a-Bisabolene; (Z)-b-Ocimene; a- Terpinyl acetate; a-Cubebene; Caryophyllene oxide; Caryophyllene oxide isomer; a- Phellandrene; Pseudolimonene; Geranyl formate; a-Copaene; Geranyl tiglate; (E)-g- Atlantone; (2E,6E)-Famesyl acetate; epi-Cubebol; a-Selinene; Bicyclogermacrene; 6-Methyl- 5-hepten-2-one; Octan-3-one; Isoneral; neo-Menthol; trans-a-Bergamotene; a-Humulene; Menthyl acetate; Lavandulyl acetate; Bomeol; Benzyl acetate; (E)^-Ocimene; Leptospermone; a-Fenchene; Camphene; 3-Methylcyclohexanone; a-Ylangene; Neryl acetate; Geranic acid; Benzyl benzoate; Decanol; Citronellyl formate; Isomenthone; Menthofuran; A3-Carene; (E)-a-Atlantone; g-Himachalene; trans-Calamenene; d-Cadinene; g-Dehydro-ar-himachalene; Geranyl isobutyrate; a-Thujene; Geranyl acetate; a-Terpinene; para-Methylanisole; Menthone; Myrcene; Octan-3-ol; a-Himachalene; cis-a-Bergamotene; b- Caryophyllene; a-Terpineol; Germacrene D; 11-aH-Himachala- 1,4-diene; Citronellol; Pulegone; b-Bisabolene; Cubebol; g-Cadinene; (3E,6E)-a-Famesene; a-Muurolene; b- Himachalene; Terpinolene; para-Cymenene; trans-Linalool oxide (fur.); Rosefuran oxide; Terpinen-4-ol; Menthol; Carvone; Neral; a-Pinene; Geranial; neo-Menthyl acetate; Sabinene; b-Pinene; Linalool; g-Terpinene; Geraniol; Linalyl acetate; para-Cymene; Limonene and/or 1,8-Cineole.

[00066] In one embodiment, the composition comprises at most 0.005% 2- Methylbutyral; at most 0.005% 2-Methylbutanol; at most 0.005% Prenol; at most 0.005% 4- Heptanone; at most 0.005% Ethanol; at most 0.005% Isovaleral; at most 0.005% Isoamyl alcohol; at most 0.005% (2E)-Hexenal; at most 0.005% trans-Rose oxide; at most 0.005% 2- Ethylfuran; at most 0.005% Hexanal; at most 0.005% (3Z)-Hexenol; at most 0.005% Geranyl benzoate; at most 0.005% 2-Methyl-3-buten-2-ol; at most 0.005% Benzaldehyde; at most 0.005% a-Bisabolol; at most 0.005% Oxypeucedanin; 0.005% to 0.01% 6-Methyl-5-hepten- 2-ol; 0.005% to 0.01% Viridiflorol; 0.005% to 0.01% 3-Methyl-3-butenyl acetate; 0.005% to 0.015% a-Gurjunene; 0.005% to 0.015% (2E,6E)-Famesal; 0.005% to 0.015% Geranyl heptanoate; 0.005% to 0.015% Hexanol; 0.005% to 0.015% Hashishene; 0.005% to 0.015% 4-Nonanol; 0.005% to 0.015% Geranyl valerate; 0.005% to 0.015% Nootkatone; 0.005% to 0.015% para-Camphorene; 0.005% to 0.015% Toluene; 0.01% to 0.02% Nonane; 0.01% to 0.02% neoiso-Menthol; 0.01% to 0.02% Thuja-2,4(10)-diene; 0.01% to 0.02% Octanol; 0.01% to 0.02% d-Elemene; 0.01% to 0.02% b-Himachalene oxide; 0.01% to 0.02% Nonanal; 0.01% to 0.02% a-Elemol; 0.01% to 0.02% a-Sinensal; 0.015% to 0.025% Octen-3- ol; 0.015% to 0.025% (Z)-a-Bisabolene; 0.015% to 0.025% Longibomeol; 0.015% to 0.025% (2E,6Z)-Famesol; 0.015% to 0.025% Grandiflorone; 0.015% to 0.025% Stearic acid; 0.015% to 0.025% Isomenthyl acetate; 0.015% to 0.025% trans-Isopiperitenol; 0.015% to 0.025% meta-Camphorene; 0.015% to 0.025% Piperitenone; 0.015% to 0.025% Cyclosativene I; 0.02% to 0.05% Tricyclene; 0.02% to 0.05% Himachalene epoxide; 0.02% to 0.05% Citropten; 0.02% to 0.05% Bergapten; 0.02% to 0.05% trans-Carveol; 0.02% to 0.05% Cyclosativene II; 0.02% to 0.05% Germacrene B; 0.02% to 0.05% Linoleic acid; 0.02% to 0.05% trans-Sabinene hydrate; 0.02% to 0.05% Verbenone; 0.02% to 0.05% Oleic acid; 0.02% to 0.05% Spathulenol; 0.02% to 0.05% trans-Chrysanthemal; 0.02% to 0.05% Deodarone epimer I; 0.02% to 0.05% Dodecanal; 0.02% to 0.05% cis-Linalool oxide (fur.); 0.02% to 0.05% Isomenthol; 0.02% to 0.05% cis-Limonene oxide; 0.02% to 0.05% trans- para-Mentha-2,8-dien-l-ol; 0.02% to 0.05% Octen-3-yl acetate; 0.02% to 0.05% Himachala- 2, 4-diene; 0.02% to 0.05% a-Agarofuran; 0.02% to 0.05% Flavesone; 0.02% to 0.05% cis- Sabinene hydrate; 0.02% to 0.05% cis-para-Menth-2-en-l-ol; 0.02% to 0.05% g-Terpineol; 0.03% to 0.07% Octanal; 0.03% to 0.07% Camphor; 0.03% to 0.07% Geranyl butyrate; 0.03% to 0.07% Humulene epoxide II; 0.03% to 0.07% 4-Nonanone; 0.03% to 0.07% b- Copaene; 0.03% to 0.07% Phenylethyl tiglate; 0.03% to 0.07% Allohimachalol; 0.03% to 0.07% ar-Himachalene; 0.03% to 0.07% a-Cadinene; 0.03% to 0.07% Lavandulol; 0.03% to 0.07% Ethyl benzoate; 0.03% to 0.07% Octyl acetate; 0.03% to 0.07% a-Santalene; 0.03% to 0.07% Piperitone; 0.03% to 0.07% Palmitic acid; 0.03% to 0.07% trans-Cadina- 1(6), 4-diene; 0.03% to 0.07% Methyl benzoate; 0.03% to 0.07% Limona ketone; 0.03% to 0.07% Octan-3- yl acetate; 0.05% to 0.1% Decanal; 0.05% to 0.1% para-Cymen-8-ol; 0.05% to 0.1% Longifolene; 0.05% to 0.1% Caryophyllenyl alcohol; 0.05% to 0.1% Prenyl benzoate; 0.05% to 0.1% Isoleptospermone; 0.05% to 0.1% (E)-Isoeugenol; 0.05% to 0.1% (E)-Vestitenone; 0.05% to 0.1% Citronellyl propionate; 0.05% to 0.1% b-Elemene; 0.05% to 0.1% a-Cadinol; 0.05% to 0.1% Citronellyl acetate; 0.05% to 0.1% Eugenol; 0.05% to 0.1% b-Atlantone; 0.05% to 0.1% (E)-10,ll-Dihydroatlantone; 0.05% to 0.1% (2E,6E)-Famesol; 0.05% to 0.1% Bomyl acetate; 0.07% to 0.15% x-Muurolol; 0.07% to 0.15% Cubenol; 0.07% to 0.15% x- Cadinol; 0.07% to 0.15% (Z)-a-Atlantone; 0.07% to 0.15% b-Selinene; 0.07% to 0.15% 1,5- diepi^-Bourbonene; 0.07% to 0.15% b-Bourbonene; 0.07% to 0.15% Citronellal; 0.07% to 0.15% exo-Isocitral; 0.07% to 0.15% Epoxyterpinolene; 0.07% to 0.15% Isogeranial; 0.07% to 0.15% 1-Terpineol; 0.07% to 0.15% trans-Limonene oxide; 0.07% to 0.15% lO-epi-g- Eudesmol; 0.07% to 0.15% 6,9-Guaiadiene; 0.1% to 0.2% Himachalol; 0.1% to 0.2% Citronellyl butyrate; 0.1% to 0.2% cis-Rose oxide; 0.1% to 0.2% endo-Fenchol; 0.1% to 0.2% b-Thujone; 0.1% to 0.2% b-Santalene; 0.1% to 0.2% (E)^-Famesene; 0.1% to 0.2% (Z)-y-Atlantone; 0.1% to 0.2% Nerol; 0.1% to 0.2% (E)-a-Bisabolene; 0.1% to 0.2% (Z)-b- Ocimene; 0.1% to 0.2% a-Terpinyl acetate; 0.1% to 0.2% a-Cubebene; 0.1% to 0.2% Caryophyllene oxide; 0.1% to 0.2% Caryophyllene oxide isomer; 0.1% to 0.2% a- Phellandrene; 0.1% to 0.2% Pseudolimonene; 0.1% to 0.2% Geranyl formate; 0.1% to 0.2% a-Copaene; 0.1% to 0.2% Geranyl tiglate; 0.1% to 0.2% (E)-y-Atlantone; 0.15% to 0.25% (2E,6E)-Famesyl acetate; 0.15% to 0.25% epi-Cubebol; 0.15% to 0.25% a-Selinene; 0.15% to 0.25% Bicyclogermacrene; 0.15% to 0.25% 6-Methyl-5-hepten-2-one; 0.15% to 0.25% Octan-3-one; 0.15% to 0.25% Isoneral; 0.15% to 0.25% neo-Menthol; 0.15% to 0.25% trans- a-Bergamotene; 0.2% to 0.5% a-Humulene; 0.2% to 0.5% Menthyl acetate; 0.2% to 0.5% Lavandulyl acetate; 0.2% to 0.5% Bomeol; 0.2% to 0.5% Benzyl acetate; 0.2% to 0.5% (E)- b-Ocimene; 0.2% to 0.5% Leptospermone; 0.2% to 0.5% a-Fenchene; 0.2% to 0.5% Camphene; 0.2% to 0.5% 3-Methylcyclohexanone; 0.2% to 0.5% a-Ylangene; 0.2% to 0.5% Neryl acetate; 0.2% to 0.5% Geranic acid; 0.2% to 0.5% Benzyl benzoate; 0.2% to 0.5% Decanol; 0.2% to 0.5% Citronellyl formate; 0.2% to 0.5% Isomenthone; 0.2% to 0.5% Menthofuran; 0.2% to 0.5% A3-Carene; 0.3% to 0.7% (E)-a-Atlantone; 0.3% to 0.7% g-

Himachalene; 0.5% to 1.0% trans-Calamenene; 0.5% to 1.0% d-Cadinene; 0.5% to 1.0% g-

Dehydro-ar-himachalene; 0.5% to 1.0% Geranyl isobutyrate; 0.5% to 1.0% a-Thujene; 0.5% to 1.0% Geranyl acetate; 0.5% to 1.0% a-Terpinene; 0.5% to 1.0% para-Methylanisole; 0.7% to 1.5% Menthone; 0.7% to 1.5% Myrcene; 0.7% to 1.5% Octan-3-ol; 0.7% to 1.5% a-

Himachalene; 0.7% to 1.5% cis-a-Bergamotene; 0.7% to 1.5% b-Caryophyllene; 0.7% to

1.5% a-Terpineol; 0.7% to 1.5% Germacrene D; 0.7% to 1.5% 11-aH-Himachala- 1,4-diene; 0.7% to 1.5% Citronellol; 0.7% to 1.5% Pulegone; 0.7% to 1.5% b-Bisabolene; 0.7% to 1.5% Cubebol; 0.7% to 1.5% g-Cadinene; 0.7% to 1.5% (3E,6E)-a-Famesene; 1.5% to 2.5% a- Muurolene; 1.5% to 2.5% b-Himachalene; 1.5% to 2.5% Terpinolene; 1.5% to 2.5% para- Cymenene; 1.5% to 2.5% trans-Linalool oxide (fur.); 1.5% to 2.5% Rosefuran oxide; 1.5% to 2.5% Terpinen-4-ol; 1.5% to 2.5% Menthol; 2.5% to 5.0% Carvone; 2.5% to 5.0% Neral; 2.5% to 5.0% a-Pinene; 2.5% to 5.0% Geranial; 2.5% to 5.0% neo-Menthyl acetate; 2.5% to 5.0% Sabinene; 2.5% to 5.0% b-Pinene; 2.5% to 5.0% Linalool; 2.5% to 5.0% g-Terpinene; 5.0% to 9.0% Geraniol; 5.0% to 9.0% Linalyl acetate; 38% to 42% para-Cymene; 38% to 42% Limonene and/or 38% to 42% 1,8-Cineole.

[00067] In another embodiment, the composition comprises Pseudotsuga menziesii(Mirb.) Franco, Pinus sylvestris I... Cupressus sempervirens I... Citrus limon, Mentha x piperita I... Thymus vulgaris (L.) ct <Linalool and/ or Juniper us communis L.

[00068] In one embodiment, the composition comprises 4.0% to 5.0% Pseudotsuga menziesii(Mirb.) Franco, 4.0% to 5.0% Pinus sylvestris L., 2.5% to 3.5% Cupressus sempervirens L., 2.0% to 3.0% Citrus limon, 2.0% to 3.0% Mentha x piperita L., 2.0% to 3.0% Thymus vulgaris (L.) ct <Linalool and/or 1.0% to 2.0 % Juniperus communis L.

[00069] In another embodiment, the composition comprises Styrene; 2-Methyl-3- buten-2-ol; 2-Ethylfuran; Ethanol; Toluene; cis-Limonene oxide; Santene; Benzaldehyde; 7- epi-a-Selinene; a-Campholenal; Bergapten; Hexanal; a-Calacorene; ortho-Cymene; allo- Aromadendrene; Octan-3-ol; Sibirene; Citropten; para-Camphorene; meta-Cymene; para- Mentha-l,3,8-triene; (3Z)-Caryophylla-3,8(13)-dien-5 -ol; meta-Cymen-8-ol; trans-Carveol; epi-Cedrol; Carvacrol; Guaia-6.1()( 14)-dien-4 -ol: meta-Camphorene; Hexanol; (2E)- Hexenal; Hashishene; Thuja-2,4(10)-diene; neo-Menthyl acetate; a-Longipinene; Isomenthyl acetate; (3Z)-Hexenol; trans-Sabinene hydrate; Thymol; trans-Cadina- 1(6), 4-diene; Camphor; Bicycloelemene; Sabinaketone; endo-Fenchol; Verbenone; cis-Linalool oxide (fur.); b-Copaene; a-Cadinol; trans-para-Menth-2-en-l-ol; Myrtenol; 2-Ethylhexanol; b- Bourbonene; x-Cadinol; d-Terpineol; a-Cedrene; d-Selinene; Spathulenol; a-Cedrol; cis- Dihydrocarvone; cis-Piperitol; (Z)^-Ocimene; b-Selinene; b-Elemene; a-Copaene; cis-para- Menth-2-en-l-ol; Linalyl acetate; Piperitone; Camphene hydrate; trans-Pinocarveol; cis-para- Mentha-2,8-dien-l-ol; para-Cymen-8-ol; Aromadendrene; Isomenthol; a-Ylangene; Hotrienol; Caryophyllene oxide isomer; Caryophyllene oxide; a-Phellandrene; Pseudolimonene; cis-Sabinene hydrate; Carvone; a-Muurolene; Longifolene; a-Amorphene; g-Muurolene; Bicyclogermacrene; Valencene; Citronellol; Tricyclene; a-Terpinyl acetate; Geranial; Bomyl acetate; Geranyl acetate; a-Humulene; b-Bisabolene; g-Cadinene; a- Thujene; Thymol methyl ether; Pulegone; (E)-b-Ocimene; Citronellyl acetate; Germacrene D; a-Terpineol; d-Cadinene; Zonarene; Bomeol; neo-Menthol; Menthyl acetate; a-Terpinene; Isomenthone; Menthofuran; para-Cymene; a-Fenchene; Camphene; b-Caryophyllene; cis-a- Bergamotene; Menthone; g-Terpinene; Myrcene; Terpinolene; Isoterpinolene; para- Cymenene; A3-Carene; Linalool; Menthol; Terpinen-4-ol; Limonene; 1,8-Cineole; b- Phellandrene; b-Pinene; Sabinene and/or a-Pinene. [00070] In another embodiment, the composition comprises at most 0.005% Styrene; at most 0.005% 2-Methyl-3-buten-2-ol; at most 0.005% 2-Ethylfuran; at most 0.005% Ethanol; at most 0.005% Toluene; at most 0.005% cis-Limonene oxide; 0.005% to 0.01% Santene; 0.005% to 0.01% Benzaldehyde; 0.005% to 0.01% 7-epi-a-Selinene; 0.005% to 0.01% a- Campholenal; 0.005% to 0.01% Bergapten; 0.005% to 0.015% Hexanal; 0.005% to 0.015% a-Calacorene; 0.005% to 0.015% ortho-Cymene; 0.005% to 0.015% allo-Aromadendrene; 0.005% to 0.015% Octan-3-ol; 0.005% to 0.015% Sibirene; 0.005% to 0.015% Citropten; 0.005% to 0.015% para-Camphorene; 0.01% to 0.02% meta-Cymene; 0.01% to 0.02% para- Mentha-l,3,8-triene; 0.01% to 0.02% (3Z)-Caryophylla-3,8(13)-dien-5 -ol; 0.01% to 0.02% meta-Cymen-8-ol; 0.01% to 0.02% trans-Carveol; 0.01% to 0.02% epi-Cedrol; 0.01% to 0.02% Carvacrol; 0.01% to 0.02% Guaia-6,10(14)-dien-4 -ol; 0.015% to 0.025% meta- Camphorene; 0.015% to 0.025% Hexanol; 0.015% to 0.025% (2E)-Hexenal; 0.015% to 0.025% Hashishene; 0.02% to 0.05% Thuja-2,4(10)-diene; 0.02% to 0.05% neo-Menthyl acetate; 0.02% to 0.05% a-Longipinene; 0.02% to 0.05% Isomenthyl acetate; 0.02% to 0.05% (3Z)-Hexenol; 0.02% to 0.05% trans-Sabinene hydrate; 0.02% to 0.05% Thymol; 0.02% to 0.05% trans-Cadina- 1(6), 4-diene; 0.02% to 0.05% Camphor; 0.02% to 0.05% Bicycloelemene; 0.02% to 0.05% Sabinaketone; 0.02% to 0.05% endo-Fenchol; 0.02% to 0.05% Verbenone; 0.03% to 0.07% cis-Linalool oxide (fur.); 0.03% to 0.07% b-Copaene; 0.03% to 0.07% a-Cadinol; 0.03% to 0.07% trans-para-Menth-2-en-l-ol; 0.03% to 0.07% Myrtenol; 0.03% to 0.07% 2-Ethylhexanol; 0.03% to 0.07% b-Bourbonene; 0.03% to 0.07% x-Cadinol; 0.03% to 0.07% d-Terpineol; 0.03% to 0.07% a-Cedrene; 0.03% to 0.07% d- Selinene; 0.03% to 0.07% Spathulenol; 0.03% to 0.07% a-Cedrol; 0.03% to 0.07% cis- Dihydrocarvone; 0.03% to 0.07% cis-Piperitol; 0.05% to 0.1% (Z)^-Ocimene; 0.05% to 0.1% b-Selinene; 0.05% to 0.1% b-Elemene; 0.05% to 0.1% a-Copaene; 0.05% to 0.1% cis- para-Menth-2-en-l-ol; 0.05% to 0.1% Linalyl acetate; 0.05% to 0.1% Piperitone; 0.07% to 0.15% Camphene hydrate; 0.07% to 0.15% trans-Pinocarveol; 0.07% to 0.15% cis-para- Mentha-2,8-dien-l-ol; 0.07% to 0.15% para-Cymen-8-ol; 0.07% to 0.15% Aromadendrene; 0.07% to 0.15% Isomenthol; 0.07% to 0.15% a-Ylangene; 0.07% to 0.15% Hotrienol; 0.07% to 0.15% Caryophyllene oxide isomer; 0.07% to 0.15% Caryophyllene oxide; 0.1% to 0.2% a-Phellandrene; 0.1% to 0.2% Pseudolimonene; 0.1% to 0.2% cis-Sabinene hydrate; 0.1% to 0.2% Carvone; 0.1% to 0.2% a-Muurolene; 0.1% to 0.2% Longifolene; 0.1% to 0.2% a- Amorphene; 0.1% to 0.2% g-Muurolene; 0.1% to 0.2% Bicyclogermacrene; 0.1% to 0.2% Valencene; 0.1% to 0.2% Citronellol; 0.1% to 0.2% Tricyclene; 0.15% to 0.25% a-Terpinyl acetate; 0.2% to 0.5% Geranial; 0.2% to 0.5% Bomyl acetate; 0.2% to 0.5% Geranyl acetate; 0.2% to 0.5% a-Humulene; 0.2% to 0.5% b-Bisabolene; 0.2% to 0.5% g-Cadinene; 0.2% to 0.5% a-Thujene; 0.2% to 0.5% Thymol methyl ether; 0.2% to 0.5% Pulegone; 0.2% to 0.5% (E)- -Ocimene; 0.2% to 0.5% Citronellyl acetate; 0.3% to 0.7% Germacrene D; 0.3% to 0.7% a-Terpineol; 0.3% to 0.7% d-Cadinene; 0.3% to 0.7% Zonarene; 0.3% to 0.7% Bomeol; 0.3% to 0.7% neo-Menthol; 0.3% to 0.7% Menthyl acetate; 0.5% to 1.0% a-Terpinene; 0.5% to 1.0% Isomenthone; 0.5% to 1.0% Menthofuran; 0.5% to 1.0% para-Cymene; 0.7% to 1.5% a-Fenchene; 0.7% to 1.5% Camphene; 1.0% to 2.0% b-Caryophyllene; 1.0% to 2.0% cis-a- Bergamotene; 2.0% to 5.0% Menthone; 2.0% to 5.0% g-Terpinene; 2.0% to 5.0% Myrcene; 2.0% to 5.0% Terpinolene; 2.0% to 5.0% Isoterpinolene; 2.0% to 5.0% para-Cymenene; 2.0% to 5.0% A3-Carene; 5.0% to 9.0% Linalool; 5.0% to 9.0% Menthol; 5.0% to 9.0% Terpinen-4-ol; 11% to 15% Limonene; 11% to 15% 1,8-Cineole; 11% to 15% b- Phellandrene; 15% to 19% b-Pinene; 15% to 19% Sabinene and/or 19% to 23% a-Pinene. [00071] In one embodiment, the composition comprises Citrus aurantium var. bergamia, Copaifera officinalis, Lavandula latifolia, Zingiber officinale Roscoe, Artemisia ludoviciana type latiloba ct Esters, Lavandula angustifolia, Pelargonium graveolens var roseum, Cinnamomum camphora ct 1,8 cineole. Melaleuca ericifolia Sm., Boswellia carterii, Boswellia carteri Birdw, Helichrysum italicum(Roth) G.Don, Nardostachys jatamansi D.C., Matricaria recutita I... Anthemis nobilis, Eugenia caryophyllata, Jasminum grandiflorum I... Melaleuca quinquenervia ctnerolidol and/ or Zingiber officinale Roscoe.

[00072] In another embodiment, the composition comprises 1.5% to 2.5% Citrus aurantium var. bergamia, 1.5% to 2.5% Copaifera officinalis, 1.5% to 2.5% Lavandula latifolia, 1.5% to 2.5% Zingiber officinale Roscoe, 1.0% to 2.0% Artemisia ludoviciana type latiloba ct Esters, 1.0% to 2.0% Lavandula angustifolia, 1.0% to 2.0% Pelargonium graveolens var roseum, 1.0% to 2.0% Cinnamomum camphora ct 1,8 cineole, 0.5% to 1.5% Melaleuca ericifolia Sm., 0.5% to 1.5% Boswellia carterii, 0.5% to 1.5% Boswellia carteri Birdw, 0.5% to 1.5% Helichrysum italicum(Roth) G.Don, 0.1% to 1.0% Nardostachys jatamansi D.C.. 0.1 % to 0.5% Matricaria recutita L., 0.1% to 0.5% Anthemis nobilis, 0.1% to 0.5% Eugenia caryophyllata, 0.1% to 0.5% Jasminum grandiflorum L., 0.1% to 0.5% Melaleuca quinquenervia ctnerolidol and/or 0.1% to 0.5% Zingiber officinale Roscoe.

[00073] In one embodiment, the composition comprises Salvia sclarea L., Eucalyptus radiate, Boswellia carterii, Citrus limon, citrus reticulata, Citrus sinensis (l.) osbeck, Mentha piperita, Rosmarinus officinalis (L.) ct cineole, Mentha spicata L. and Melaleuca alternifolia. [00074] In another embodiment, the composition comprises 1.5% to 2.5% Salvia sclarea L., 0.5% to 1.5% Eucalyptus radiate, 1.0% to 2.0% Boswellia carterii, 3.0% to 4.0% Citrus limon, 3.0% to 4.0% citrus reticulata, 2.0% to 3.0% Citrus sinensis (l.) osbeck, 1.5% to 2.5% Mentha piperita, 1.5% to 2.5% Rosmarinus officinalis (L.) ct cineole, 1.0% to 2.0% Mentha spicata L. and/or 0.5% to 1.5% Melaleuca alternifolia.

[00075] In one embodiment, the composition comprises Mentha x piperita, Mentha arvensis, Bursera graveolens, Boswellia frereana, Kaempferia galangal, Zingiber officinale Roscoe, Pseudotsuga menziesii(Mirb.) Franco, Juniperus communis L., Eucalyptus dives, Cedrus atlantica, Santalum austrocaledonicum Vieill, Eugenia caryophyllata and/or Commiphora guidottii.

[00076] In another embodiment, the composition comprises 4.0% to 6.0% Mentha x piperita, 1.0% to 3.0% Mentha arvensis, 1.0% to 3.0% Bursera graveolens, 1.0% to 3.0% Boswellia frereana, 1.0% to 3.0% Kaempferia galangal, 1.0% to 3.0% Zingiber officinale Roscoe, 1.0% to 2.0% Pseudotsuga menziesii(Mirb.) Franco, 1.0% to 2.0% Juniperus communis L., 0.5% to 1.5% Eucalyptus dives, 0.1% to 1.0% Cedrus atlantica, , 0.1% to 1.0% Santalum austrocaledonicum Vieill, 0.05% to 0.3% Eugenia caryophyllata and/or 0.05% to 0.3% Commiphora guidottii.

[00077] In one embodiment, the composition comprises Styrax tonkinensis, Citrus aurantium var. bergamia, Elettaria cardamomum, Cinnamomum zeylanicum, Salvia sclarea L., Eugenia caryophyllata, Theobroma cacao, Cistus ladaniferus, Vitis vinifera, Artemisia pollens, Pelargonium graveolensL'H r., Zingiber officinale Roscoe, Humulus lupulus, Commiphora guidottii, Cryptocaria Massoy, Citrus sinensis, Myroxylon balsamum var. pereirae, Rosa x damascene, Santalum spicatum, Fokienia hodginsii, Zanthoxylum armatum and/or Vanilla planifolia.

[00078] In another embodiment, the composition comprises 0.5% to 1.5% Styrax tonkinensis, 0.5% to 1.5% Citrus aurantium var. bergamia, 0.1% to 1.0% Elettaria cardamomum, 0.1% to 0.5% Cinnamomum zeylanicum, 0.5% to 1.5% Salvia sclarea L., 1.0% to 3.0% Eugenia caryophyllata, 0.5% to 1.5% 0.01% to 0.1% Theobroma cacao, 0.01% to 0.1% Cistus ladaniferus, 0.5% to 1.5% Vitis vinifera, 1.0% to 3.0% Artemisia pollens, 0.1% to 1.0% Pelargonium graveolensL'H r. , 1.0% to 3.0% Zingiber officinale Roscoe, 0.5% to 1.5% Humulus lupulus, 0.01% to 0.05% Commiphora guidottii, 0.5% to 1.5% Cryptocaria Massoy, 0.1% to 1.0% Citrus sinensis, 1.5% to 3.0% Myroxylon balsamum var. pereirae, 0.05% to 0.3% Rosa x damascene, 0.01% to 0.1% Santalum spicatum, 0.5% to 1.5% Fokienia hodginsii and/or 1.0% to 3.0% Vanilla planifolia.

[00079] In a non-limiting preferred embodiment, compositions for use in the invention comprise: a blend of at least one primary essential oil and at least one secondary essential oil, wherein the blend is in an amount of from about 15% to about 25% by volume; vegetable glycerin in an amount of about 75% to about 85% by volume; water in an amount of about 5% to about 15% by volume; and an emulsifier.

[00080] In another embodiment of the invention, the emulsifier is in an amount of from about 5% to about 95% by volume, from about 10% to about 90% by volume, from about 15% to about 95% by volume, from about 20% to about 90% by volume, from about 25% to about 85% by volume, from about 30% to about 80% by volume, from about 35% to about 75% by volume, from about 40% to about 70% by volume, from about 45% to about 65% by volume, from about 50% to about 60% by volume, from about 5% to about 10% by volume, from about 5% to about 20% by volume, from about 5% to about 25% by volume, from about 5% to about 30% by volume, from about 5% to about 35% by volume, from about 5% to about 40% by volume, from about 5% to about 45% by volume, from about 5% to about 50% by volume, from about 5% to about 55% by volume, from about 5% to about 60% by volume, from about 5% to about 65% by volume, from about 5% to about 70% by volume, from about 5% to about 75% by volume, from about 5% to about 80% by volume, from about 5% to about 90% by volume, from about 90% to about 95% by volume, from about 85% to about 95% by volume, from about 80% to about 95% by volume, from about 75% to about 95% by volume, from about 70% to about 95% by volume, from about 65% to about 95% by volume, from about 60% to about 95% by volume, from about 55% to about 95% by volume, from about 50% to about 95% by volume, from about 45% to about 95% by volume, from about 40% to about 95% by volume, from about 35% to about 95% by volume, from about 30% to about 95% by volume, from about 25% to about 95% by volume, from about 20% to about 95% by volume, from about 15% to about 95% by volume, from about 10% to about 95% by volume of the aromatherapy composition.

[00081] In one embodiment, the emulsifier is selected from the group consisting of salts of fatty acids such as myristic acid, palmitic acid, stearic acid, oleic acid, monoglyceride ester of diacetyltartaric acid, diglyceride ester of diacetyltartaric acid, monoglyceride ester of citric acid and salts thereof, diglyceride ester of citric acid, monoglyceride ester of lactic acid, diglyceride ester of lactic acid, dioctyl sodium sulfosuccinate, monoglyceride ester of phosphoric acid, diglyceride ester of phosphoric acid, lecithin, hydoxylated lecithin, lysolecithin, polysorbates, sorbitan esters of myristic acid, sorbitan ester of palmitic acid, sorbitan ester of stearic acid, sorbitan ester of oleic acid, polyglycerol esters of myristic acid, polyglycerol esters of palmitic acid, polyglycerol esters of stearic acid, polyglycerol esters of oleic acid, monoglyceride esters of myristic acid, monoglyceride esters of palmitic acid, monoglyceride esters of stearic acid, monoglyceride esters of oleic acid, diglyceride esters of myristic acid, diglyceride esters of palmitic acid, diglyceride esters of stearic acid, diglyceride esters of oleic acid, (ethoxy)n monoglyceride esters of myristic acid, (ethoxy ) _n monoglyceride esters of palmitic acid, (ethoxy ) _n monoglyceride esters of stearic acid, (ethoxy)n monoglyceride esters of oleic acid, (ethoxy )n diglyceride esters of myristic acid, (ethoxy)n diglyceride esters of palmitic acid, (ethoxy)n diglyceride esters of stearic acid, (ethoxy ) _n diglyceride esters of oleic acid, sucrose ester of lauric acid, sucrose ester of myristic acid, sucrose ester of palmitic acid, sucrose ester of stearic acid, sucrose ester of oleic acid, propylene glycol ester of lauric acid, propylene glycol ester of myristic acid, propylene glycol ester of palmitic acid, propylene glycol ester of stearic acid, propylene glycol ester of oleic acid, modified starches such as sodium octenyl succinate starch, acetylated distarch phosphate, hydroxypropyl starch and oxidized starch, wherein n is a whole number from 10 to 30.

[00082] In another embodiment of the invention, the emulsifier is at least one of salts of fatty acids such as myristic acid, palmitic acid, stearic acid, oleic acid, monoglyceride ester of diacetyltartaric acid, diglyceride ester of diacetyltartaric acid, monoglyceride ester of citric acid and salts thereof, diglyceride ester of citric acid, monoglyceride ester of lactic acid, diglyceride ester of lactic acid, dioctyl sodium sulfosuccinate, monoglyceride ester of phosphoric acid, diglyceride ester of phosphoric acid, lecithin, hydoxylated lecithin, lysolecithin, polysorbates, sorbitan esters of myristic acid, sorbitan ester of palmitic acid, sorbitan ester of stearic acid, sorbitan ester of oleic acid, polyglycerol esters of myristic acid, polyglycerol esters of palmitic acid, polyglycerol esters of stearic acid, polyglycerol esters of oleic acid, monoglyceride esters of myristic acid, monoglyceride esters of palmitic acid, monoglyceride esters of stearic acid, monoglyceride esters of oleic acid, diglyceride esters of myristic acid, diglyceride esters of palmitic acid, diglyceride esters of stearic acid, diglyceride esters of oleic acid, (ethoxy )n monoglyceride esters of myristic acid, (ethoxy )n monoglyceride esters of palmitic acid, (ethoxy )n monoglyceride esters of stearic acid,

(ethoxy )n monoglyceride esters of oleic acid, (ethoxy )n diglyceride esters of myristic acid, (ethoxy )n diglyceride esters of palmitic acid, (ethoxy )n diglyceride esters of stearic acid, (ethoxy )n diglyceride esters of oleic acid, sucrose ester of lauric acid, sucrose ester of myristic acid, sucrose ester of palmitic acid, sucrose ester of stearic acid, sucrose ester of oleic acid, propylene glycol ester of lauric acid, propylene glycol ester of myristic acid, propylene glycol ester of palmitic acid, propylene glycol ester of stearic acid, propylene glycol ester of oleic acid, modified starches such as sodium octenyl succinate starch, acetylated distarch phosphate, hydroxypropyl starch and oxidized starch, wherein n is a whole number from 10 to 30.

[00083] In one embodiment of the invention, emulsifier is in an amount of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% in the aromatherapy composition.

[00084] In another embodiment of the invention, the water is in an amount of from about 5% to about 95% by volume, from about 10% to about 90% by volume, from about 15% to about 95% by volume, from about 20% to about 90% by volume, from about 25% to about 85% by volume, from about 30% to about 80% by volume, from about 35% to about 75% by volume, from about 40% to about 70% by volume, from about 45% to about 65% by volume, from about 50% to about 60% by volume, from about 5% to about 10% by volume, from about 5% to about 20% by volume, from about 5% to about 25% by volume, from about 5% to about 30% by volume, from about 5% to about 35% by volume, from about 5% to about 40% by volume, from about 5% to about 45% by volume, from about 5% to about 50% by volume, from about 5% to about 55% by volume, from about 5% to about 60% by volume, from about 5% to about 65% by volume, from about 5% to about 70% by volume, from about 5% to about 75% by volume, from about 5% to about 80% by volume, from about 5% to about 90% by volume, from about 90% to about 95% by volume, from about 85% to about 95% by volume, from about 80% to about 95% by volume, from about 75% to about 95% by volume, from about 70% to about 95% by volume, from about 65% to about 95% by volume, from about 60% to about 95% by volume, from about 55% to about 95% by volume, from about 50% to about 95% by volume, from about 45% to about 95% by volume, from about 40% to about 95% by volume, from about 35% to about 95% by volume, from about 30% to about 95% by volume, from about 25% to about 95% by volume, from about 20% to about 95% by volume, from about 15% to about 95% by volume, from about 10% to about 95% by volume of the aromatherapy composition.

[00085] In another embodiment of the invention, the water is in an amount of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% in the aromatherapy composition.

[00086] In one embodiment, the at least one primary essential oil and at least one secondary essential oil are selected from the group that includes spearmint, cinnamon leaf, nutmeg, rosemary, cardamom, frankincense, ginger, bergamot, melissa, eucalyptus lemon, caraway, sughanda kokila, clary sage, sage, black pepper, holy basil, grapefruit, litsea cubeba, and coffee C02. In another embodiment, the composition further includes an emulsifier. [00087] In another embodiment of the invention, the primary essential oil is at least one of spearmint, cinnamon leaf, nutmeg, rosemary, cardamom, frankincense, ginger, bergamot, melissa, eucalyptus lemon, caraway, sughanda kokila, clary sage, sage, black pepper, holy basil, grapefruit, litsea cubeba, and coffee C02.

[00088] In another embodiment of the invention, the secondary essential oil is at least one of spearmint, cinnamon leaf, nutmeg, rosemary, cardamom, frankincense, ginger, bergamot, melissa, eucalyptus lemon, caraway, sughanda kokila, clary sage, sage, black pepper, holy basil, grapefruit, litsea cubeba, and coffee C02.

[00089] In one embodiment, the at least one primary essential oil and at least one secondary essential oil are selected from the group that includes spearmint, cinnamon leaf, nutmeg, rosemary, cardamom, frankincense, ginger, bergamot, melissa, eucalyptus lemon, caraway, sughanda kokila, clary sage, sage, black pepper, holy basil, grapefruit, litsea cubeba, and coffee C02.

[00090] In another embodiment of the invention, the composition comprises a diluent. In a specific embodiment, the blend of at least one primary essential oil and at least one secondary essential is in an amount of 100% without diluent.

[00091] In certain embodiments, the compositions of the invention are prepared so that they are similar to nasal secretions, so that normal ciliary action is maintained. Thus, in some embodiments the aqueous nasal solutions to be nebulized usually are isotonic or slightly buffered to maintain a pH of about 5.5 to about 6.5. In addition, antimicrobial preservatives, similar to those used in ophthalmic preparations, drugs, or appropriate drug stabilizers, if required, may be included in the formulation. For example, various commercial nasal preparations are known and include drugs such as antibiotics or antihistamines.

[00092] The compositions of the invention must be stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less than 0.5 ng/mg protein.

[00093] In another aspect, the invention relates to a kit having at least two containers, comprising: the essential oil emulsion in a first container and a further therapeutic agent in a second container. In one embodiment of the invention, the kit further comprises a dilution buffer in a third container. [00094] In sum, the compositions of essential oil blends and emulsifications provide a therapeutic effect. The composition’s emulsification of essential oils increases delivery and bioavailability of pharmacologically active essential oil components. Without emulsification, essential oil solutions may stratify and prevent uniform delivery of molecular components, i.e., different physiochemical properties of components will cause lighter molecules to be aerosolized at different times than heavier components within the same mixture, thereby preventing synergistic effects that rely on multiple components acting at the same time. Without specific emulsifiers, oxidation of pharmacologically active essential oils may occur rapidly, thereby diminishing or eliminating the therapeutic effect.

Methods for Delivering Compositions

[00095] Aspects of the invention include a method for providing a therapeutic effect in a subject by administering the composition(s) of the invention via intranasal, aerosolization, orthonasal, retronasal, topical or transdermal delivery.

[00096] In an embodiment, the essential oil compositions are safely delivered to a subject through a personal aromatherapy diffuser or vaporizer.

[00097] In one embodiment, the composition(s) are diffused by a diffuser.

[00098] In a specific embodiment, the diffuser is selected from the group that includes a nebulizer diffuser, an ultrasonic or humidifying diffuser, and evaporative diffuser, and a heat diffuser.

[00099] In a more specific embodiment, the composition(s) are diffused by a heat diffuser.

[000100] In another embodiment, the maximum temperature of the heat diffuser is less than or equal to 80 °F.

[000101] In another embodiment, the maximum temperature of the heat diffuser is less than or equal to 100 °F.

[000102] In another embodiment, the maximum temperature of the heat diffuser is less than or equal to 120 °F.

[000103] In a further embodiment of the invention, the maximum temperature of the heat diffuser is less than or equal to 60°F, 65°F, 70°F, 75°F, 85°F, 90°F, 95°F°, 105°F, 110°F, 115°F, 125°F, 130°F, 135°F, or 140°F.

[000104] In yet another aspect, the invention provides essential oil compositions for use in portable aromatherapy diffusers and vaporizers which when vaporized, deliver an effective amount of terpenes to the subject without diffusing significant scent into the ambient around the subject.

[000105] Higher heat vaporizer devices yield smaller particle size, but also destroy active components. Higher heat vaporizer devices create particles that are too small to be absorbed in the nasal sinuses and instead travel to the lung or are expelled.

[000106] Glycerol and emulsifiers greatly enhance intranasal absorption which allows efficient delivery of pharmacologically active components that does not occur without the present invention’s delivery method and excipient formulation.

[000107] For administration by inhalation, the essential oil compositions may be delivered in the form of an aerosol spray from pressurized packs with the use of a suitable propellant, e.g., carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges that contain the essential oil compositions may be used in an inhaler or insufflator.

[000108] Low-heat combined with negative pressure allows for aerosolization of small particles consisting of a uniform mixture of pharmacologically active essential oil components within droplets of glycerol and emulsifiers.

[000109] For transdermal administration, the essential oil compositions may be delivered in the form of a patch, liquid, gel, solvent, reservoir or liquid diluent.The essential oil composition may also be administered with a solubilizing agent.

[000110] In a further embodiment, the essential oil compositions are admistered transdermally with a solubilizing agent that may be an ionic liquid, fatty acid, alcohol, nanoemulsion, liposome, noisome, transfersome, ethosome, dendrimer, liquid nanoparticle, polymeric nanoparticle, carbon nanotube or fullerene.

[000111] In another embodiment, transdermal administration of the essential oil compositions may be performed with microneedles, microdermabrasions, thermal ablations, ultrasound, electrotransport, microporation or nanoporation.

[000112] In one embodiment, transdermal administration of the essential oil compositions occur through diffusion.

[000113] For topical administration, the essential oil compositions may be delivered in the form of a patch, cream, ointment, salve, gel, reservoir, lotion, spray or a substrate saturated with the essential oil composition. The saturated substrate may be a cloth, bandage, rag, braclet, anklet, wristband, necklace, headband or sleepmask.

[000114] In one embodiment, topical administration of the essential oil compositions occurs through diffusion. [000115] Thus, the unique formulations of the compositions and methods for delivering said compositions provide an optimal bioavailability of the pharmacologically active essential oil components.

Methods for Using Compositions

[000116] Another aspect of the invention is to provide a composition that elicits a therapeutic effect to treat symptoms in a subject.

[000117] In one embodiment, an essential oil composition of the invention is used to improve cognitive function in a subject in need thereof.

[000118] In one embodiment, an essential oil composition of the invention is used to improve cognitive function according to electroencephalography (EEG) studies in a subject in need thereof.

[000119] In one embodiment, an essential oil composition of the invention is used to improve cognitive function by measuring alpha, theta or gamma waves of a subject in need thereof.

[000120] In another embodiment, an essential oil composition of the invention is used to improve chemosensory sensations in a subject in need thereof.

[000121] In a specific embodiment, an essential oil composition of the invention is used to improve visual acuity according to testing using the Pelli-Robson contrast sensitivity test in a subject in need thereof.

[000122] In another embodiment, an essential oil composition of the invention is used to improve visual acuity according to testing using the logMAR test in a subject in need thereof. [000123] In yet a further embodiment, an essential oil composition of the invention is used to increase cognitive flexibility in a subject in need thereof.

[000124] In one embodiment, an essential oil composition of the invention is used to improve cognitive flexibility according to the Stroop test in a subject in need thereof.

[000125] In yet a further embodiment, an essential oil composition of the invention increases verbal fluency in a subject in need thereof.

[000126] In another embodiment, an essential oil composition of the invention increases verbal fluency according to semantic or phonemic tests in a subject in need thereof.

[000127] In another embodiment, an essential oil composition of the invention is used to increase arithmetic speed in a subject in need thereof.

[000128] In yet another embodiment, an essential oil composition of the invention is used to increase time in a flow state in a subject in need thereof. [000129] In another embodiment, an essential oil composition of the invention is used to increase the energy levels in a subject in need therof.

[000130] In one embodiment, an essential oil composition of the invention is used to increase energy levels according to basal metabolic rate testing or resting metabolic rate testing in a subject in need thereof.

[000131] In another embodiment, an essential oil composition of the invention is used to reduce inflammation in a subject in need thereof.

[000132] In one embodiment, an essential oil composition of the invention is used to reduce inflammation according to blood test detecting erythrocyte sedimentionation rates in a subject in need thereof.

[000133] In one embodiment, an essential oil composition of the invention is used to reduce inflammation according to blood test detecting the concetration of C-Reactive Protein in a subject in need thereof.

[000134] In another embodiment, an essential oil composition of the invention is used to provide pain relief to a subject in need therof.

[000135] In one embodiment, an essential oil composition of the invention is used to provide pain relief according to a pain scale, such as the Wong-Baker scale, in a subject in need thereof.

[000136] In another embodiment, an essential oil composition of the invention is used to improve the digestive health to a subject in need thereof.

[000137] In one embodiment, an essential oil composition of the invention is used to improve digestive health according to gastrointestinal or colonic motor function tests in a subject in need thereof.

[000138] In another embodiment, an essential oil composition of the invention is used to improve the quality of sleep in a subject in need thereof.

[000139] In one embodiment, an essential oil composition of the invention is used to improve the quality of sleep according to an application or program that analyzes the amount of time slept each night prior to and subsequent of using said composition in a subject in need thereof.

[000140] In another embodiment, an essential oil composition of the invention is used to reduce anxiety in a subject in need thereof.

[000141] In one embodiment, an essential oil composition of the invention is used to reduce anxiety by measuring the blood pressure of a subject in need thereof. [000142] In one embodiment, an essential oil composition of the invention is used to reduce anxiety by measuring the heart rate or pulse rate of a subject in need thereof.

[000143] In one embodiment, an essential oil composition of the invention is used to reduce anxiety according to sudomotor testing in a subject in need thereof.

[000144] In another embodiment, an essential oil composition of the invention is used to improve the mood of a subject in need thereof.

[000145] In one embodiment, an essential oil composition of the invention is used to improve mood according to a mood scale, such as the Brief Mood Introspection Scale, in a subject in need thereof.

[000146] In another embodiment, an essential oil composition of the invention is used to improve libido in a subject in need thereof.

[000147] In one embodiment, an essential oil composition of the invention is used to improve libido according to a sexual desire scale, such as the Sexual Desire Inventroy-2 scale, in a subject in need thereof.

[000148] In another embodiment, an essential oil composition of the invention is used to treat addiction in a subject in need thereof.

[000149] In one embodiment, an essential oil composition of the invention is used to treat addiction according to the number of cigarettes used in a 24 hour period in a subject in need thereof.

[000150] In another embodiment, an essential oil composition of the invention is used to improve the function of the immune system in a subject in need thereof.

[000151] In one embodiment, an essential oil composition of the invention is used to improve the function of the immune system according to the concentration of natural killer (NK) cells in a subject in need thereof.

[000152] In another embodiment, an essential oil composition of the invention is used to improve the function of the respiratory system in a subject in need thereof.

[000153] In one embodiment, an essential oil composition of the invention is used to improve the function of the respiratory system according to spirometry tests in a subject in need thereof.

[000154] In another embodiment, an essential oil composition of the invention is used to alleviate fatigue in a subject in need thereof.

[000155] In one embodiment, an essential oil composition of the invention is used to alleviate fatigue according to psychomotor vigilance tests in a subject in need thereof. [000156] In another embodiment, an essential oil composition of the invention is used to increase low hormone levels in a subject in need thereof.

[000157] In one embodiment, an essential oil composition of the invention is used to increase low hormone levels according to hormone concentration levels within the blood of a subject in need thereof.

[000158] In another embodiment, an essential oil composition of the invention is used to improve metabolic functions in a subject in need thereof.

[000159] In one embodiment, an essential oil composition of the invention is used to improve metabolic functions according to basal metabolic rate testing or resting metabolic rate testing in a subject in need thereof.

[000160] The amount of the essential oil composition of the invention, and by extension the pharmacologically active essential oil components of the invention administered will, of course, be dependent on the subject being treated, on the subject’s weight, the severity of the affliction, the particular intranasal delivery method, and the judgment of the prescribing physician.

[000161] In another embodiment, an essential oil composition is used to enhance eyesight by increasing visual acuity and contrast sensitivity.

[000162] In another embodiment, an essential oil compositon is used to provide a dynamic, multi-modal aromatherapy treatment with numerous specific beneficial physiological effects resulting from additive or synergistic effects greater than the sum total of its components. [000163] In another embodiment, an essential oil compositon is used to increase alpha and theta waves of in a subject in need thereof.

[000164] In one embodiment, an essential oil composition of the invention is used to increase alpha and theta waves according to EGG tests in a subject in need thereof.

[000165] In another embodiment, an essential oil compositon is used to provide any of the following benefits in a subject in need thereof: increased creativity, increased timeliness, increased lateral thinking, increased efficient workflow, increased problem solving abilities, increased confidence, increased productivity and increased intuition.

[000166] In another embodiment, an essential oil compositon is used to improve the mood and create a stronger sense of connection within a subject in need thereof.

[000167] In another embodiment, an essential oil compositon is used to improve the memory of a subject in need thereof.

[000168] In one embodiment, an essential oil compositon is used to improve memory according to a memory scale, such as the Wechsler Memory Scale, in a subject in need thereof. [000169] In another embodiment, an essential oil compositon is used to treat the symptoms of depression and seasonal affective disorder in a subject in need thereof. These symptoms can be fatigue, loss of focus, low enthusiasm or increased stress.

[000170] In another embodiment, an essential oil compositon is used to act as anti microbial, anti-inflammatory, and/or digestive aid in a subject in need thereof.

[000171] In one embodiment, an essential oil compositon is used to improve the confidence of a subject in need thereof.

[000172] In another embodiment, an essential oil compositon is used to improve confidence according to a self-confidence or self-esteem tests taken by a subject in need thereof. [000173] In one embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, cognitive function improves by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, cognitive function may improve by about 20% as measured by tests associated with the CHC theory, the Luria theory, or the Cross-Battery approaches and models of cognitive abilities.

[000174] In one embodiment, when the essential oil emulsification of the invention is administered to a subject in need thereof, visual accuity improves by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil emulsification of the invention is administered to a subject in need thereof, cognitive function may improve by about 20% as measured by the Pelli-Robson or logMAR tests.

[000175] In one embodiment, when the essential oil emulsification of the invention is administered to a subject in need thereof, cognitive flexibility improves by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil emulsification of the invention is administered to a subject in need thereof, cognitive function may improve by about 20% as measured by the Stroop test.

[000176] In one embodiment, when the essential oil emulsification of the invention is administered to a subject in need thereof, arithmetic speed improves by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art.

[000177] In one embodiment, when an essential oil emulsification of the invention is administered to a subject in need thereof, flow state improves by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art.

[000178] In another embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, verbal fluency improves by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, verbal fluency may improve by about 20% as measured by semantic or phonemic tests.

[000179] In one embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, energy levels improve by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, energy levels may improve by about 20% as measured by basal metabolic rate testing or resting metabolic rate testing.

[000180] In another embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, inflammation is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, an inflammation reponse may be reduced by about 20% as measured by blood test detecting erythrocyte sedimentionation rates or blood test detecting the concetration of C-Reactive Protein.

[000181] In one embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, pain is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, pain may reduced by about 20% as measured by a pain scale, such as the Wong-Baker scale.

[000182] In another embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, digestive health is improved by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, digestive health may be improved by about 20% as measured by gastrointestinal or colonic motor function tests. [000183] In one embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, sleep is improved by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, sleep may be improved by about 20% as measured by an application or program that analyzes the amount of time slept each night prior to and subsequent of using said composition.

[000184] In another embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, anxiety is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, anxiety may be reduced by about 20% as measured by an blood pressure readings, heart rate monitoring or sudomotor testing. [000185] In one embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, mood is improved by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, mood may be improved by about 20% as measured by a mood scale, such as the Brief Mood Introspection Scale.

[000186] In another embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, libido is improved by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, libido may be improved by about 20% as measured by a sexual desire scale, such as the Sexual Desire Inventroy-2 scale.

[000187] In one embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, addiction is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, addiction may be reduced by about 20% as measured by the number of cigarettes used in a 24 hour period.

[000188] In another embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, the immune system’s function is improved by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, immune system function may be improved by about 20% as measured by the concentration of natural killer (NK) cells.

[000189] In one embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, respiratory functions are improved by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, respiratory functions may be improved by about 20% as measured by spirometry tests.

[000190] In another embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, fatigue is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, fatigue may be reduced by about 20% as measured by psychomotor vigilance tests.

[000191] In one embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, hormone levels are improved by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, hormone levels may be improved by about 20% as measured by hormone concentration levels within the blood.

[000192] In another embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, metabolic functions are improved by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, metabolic function levels may be improved by about 20% as measured by basal metabolic rate testing or resting metabolic rate testing.

[000193] In one embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, alpha and theta waves are improved by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, alpha and theta waves may be improved by about 20% as measured by to EGG tests.

[000194] In another embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, memory is improved by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, memory may be improved by about 20% as measured by a memory scale, such as the Wechsler Memory Scale.

[000195] In one embodiment, when an essential oil composition of the invention is administered to a subject in need thereof, confidence is improved by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art. For example, when the essential oil composition of the invention is administered to a subject in need thereof, confidence may be improved by about 20% as measured by self-confidence or self-esteem tests.

[000196] In another embodiment, when an essential oil emulsification of the invention is administered to a subject in need thereof, chemosensory improves by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% according to known techniques used in the art.

[000197] In one embodiment, the essential oil emulsification of the invention is administered concurrently with another aromatherapy treatment. In another embodiment, the essential oil emulsification of the invention is administered concurrently with another pharmaceutical treatment. In another embodiment, the essential oil emulsification of the invention is administered sequentially with another aromatherapy treatment. In yet another embodiment, the essential oil emulsification of the invention is administered sequentially with another pharmaceutical treatment.

[000198] In a further embodiment, an essential oil composition of the invention is administered at least once a week, at least twice a week, at least three times a week, at least four times a week, at least five times a week or at least six times a week. In a further embodiment, an essential oil composition of the invention is administered every day of the week.

[000199] In other embodiments, an essential oil composition of the invention is administered about every 1-8 weeks, 1-12 weeks, 1-36 weeks, 2-8 weeks, 2-12 weeks, 2-26 weeks, 2-36 weeks, 2-48 weeks, 3-4 weeks, 3-12 weeks, 3-8 weeks, 3-26 weeks, 3-36 weeks, 3-48 weeks, or 4-12 weeks. [000200] In further embodiments, an essential oil composition of the invention is administered about every 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 months, or about 1-2 months, 1-3 months, 1-4 months, 1-5 months, 1-6 months, 2-3 months, 2-4 months, 2-6 months, or 3-6 months.

[000201] In certain embodiments of the invention, an essential oil composition of the invention is administered at least yearly.

[000202] In a further embodiment, an essential oil composition is administered by having a subject breathe in the composition in 3-5 consecutive breaths. In a further embodiment, an essential oil composition is administered by having a subject breathe in the composition in 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive breaths. In a further embodiment, an essential oil composition is administered by having a subject breathe in the composition in 3-5 consecutive breaths every 2 hours.

[000203] In a further embodiment, an essential oil composition is administered by having a subject breathe in the composition in 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive breaths every 1, 2,

3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours.